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Riassunto 
WT1 é un fattore trascrizionale a dita di zinco che regola l’espressione 
di un elevato numero di geni coinvolti nel differenziamento, nel ciclo 
cellulare e nell’apoptosi. Originariamente è stato identificato come 
oncosoppressore coinvolto nella patogenesi del tumore di Wilms, un 
tumore renale pediatrico. Successivamente è stato descritto anche un 
ruolo di oncogene per WT1 in diversi tumori solidi e leucemie. La 
capacità di WT1 di attivare e/o reprimere la trascrizione dei suoi geni 
bersaglio è fortemente influenzata dal contesto cellulare e 
dall’interazione con alcuni cofattori. Recentemente abbiamo 
identificato la Kruppel-like zinc finger protein  ZNF224, come nuovo 
interattore  molecolare di WT1 e  abbiamo dimostrato che ZNF224 può 
promuovere l’attivazione trascrizionale da parte di WT1 sul gene per il 
recettore della vitamina D (VDR), noto gene bersaglio di WT1. Questi 
dati ci hanno spinto ad indagare l’effetto dell’ interazione 
ZNF224/WT1 su altri geni coinvolti nel processo apoptotico in cellule 
di leucemia mieloide cronica K562 che esprimono elevati livelli di 
WT1 endogeno. I nostri esperimenti dimostrano che ZNF224 esercita 
un duplice effetto sulla espressione dei geni bersaglio di WT1, agendo 
da co-attivatore di WT1 nella regolazione dei geni pro-apoptotici Bax, 
Bak e VDR e impedendo a WT1 di attivare i geni anti-apoptotici bag3 
e A1-Bfl-1. Successivamente,  avendo osservato che ZNF224 è poco 
espressa in linee cellulari di leucemia mieloide rispetto a WT1, 
abbiamo deciso di approfondire il ruolo di ZNF224 nel processo 
apoptotico. A tale scopo abbiamo valutato se ZNF224 venisse 
modulata in cellule  K562  in seguito a trattamento con citarabina (ara-
C), un farmaco chemioterapico comunemente impiegato nel 
trattamento delle leucemie mieloidi. Abbiamo osservato che 
l'espressione di ZNF224 è indotta da citarabina e che tale induzione 
aumenta la sensibilità delle cellule K562 al farmaco.  
I nostri risultati dimostrano l’importante ruolo che il complesso 
trascrizionale ZNF224/WT1 svolge nella modulazione di geni 
apoptotici e che l’aumento di ZNF224 indotto da ara-C può 
rappresentare uno dei meccanismi attraverso cui il farmaco induce 
apoptosi in cellule leucemiche. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
The transcription factor Wilms’ tumour gene 1, WT1, is implicated 
both in normal developmental processes and in the generation of a 
variety of solid tumors and hematological malignancies. Physical 
interactions of other cellular proteins with WT1 are known to modulate 
its function. We previously identified the Krüppel-like zinc finger 
protein, ZNF224, as a novel human WT1-associating protein that 
enhances the transcriptional activation of the human vitamin D 
receptor promoter by WT1. Here, we have analyzed the effects of 
WT1/ZNF224 interaction on the expression of apoptosis-regulating 
genes in the chronic myelogenous leukemia (CML) K562 cell line. The 
results demonstrated that ZNF224 acts in fine tuning of WT1-
dependent control of gene expression, acting as a co-activator of WT1 
in the regulation of proapoptotic genes and suppressing WT1 mediated 
trans-activation of antiapoptotitc genes. Moreover, the DNA damaging 
drug cytosine arabinoside (ara-C) induces expression of ZNF224 in 
K562 cells and this induction enhances cell apoptotic response to ara-
C. These findings suggest that ZNF224 can be a mediator of DNA 
damage-induced apoptosis in leukemia cells. 
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1.Introduction  
 
1.1  Wilms’ tumor gene 1 protein (WT1) 
        WT1 was originally defined as a tumor suppressor gene, whose 
mutations and deletions were associated with urogenital disease and 
the development of kidney tumors [1]. During embryogenesis, WT1 is 
necessary for the development of kidneys, gonads, spleen and 
mesothelial tissues as judged by severe malformations in transgenic 
mice with deleted WT1, which die in utero [2].  
WT1 consists of ten exons, encoding an mRNA transcript of about 3.2 
kb. The mRNA translates into a 429 amino acid zinc finger 
transcription factor containing an amino terminal  proline  glutamine-
rich domain, and four carboxyl terminal zinc finger domains. The 
proline  glutamine-rich domain (exons 1-6) is critical for the 
transcriptional regulatory function of WT1, being characterized by 
repression, activation, self-association, RNA-recognition domains  and 
nuclear localization signal. The carboxyl terminal region contains  
four C2H2 zinc finger, encoded by exons 7-10,  conferring specific 
DNA binding [3,4] (fig.1).  
Alternative splicing of the WT1 pre-mRNA results in four major 
isoforms: WT1(-17AA/-KTS), WT1(+17AA/-KTS), WT1(-
17AA/+KTS) and WT1(+17AA-+KTS), ranging in size between 52-
54 kDa (fig.2). The first alternative splicing event affects the entire 
exon 5, leading to presence or  absence of 17 amino acids (+/-17AA).  
The second alternative splicing event generates an insertion or a 
deletion of three amino acids, lysine, threonine and serine (+/-KTS), 
Introduction 
 
 
2 
 
encoded by exons 9, between the third and fourth zinc finger domains 
(fig.2). The +17AA isoform of WT1 has been shown to produce 
variable effects on the transcriptional function of WT1. In some cell 
types, it acts as an transcriptional activation domain, and in others it 
has been shown to constitute an independent transcriptional repression 
domain. Mice homozygous for a wt1 allele lacking exon 5 have no 
salient phenotype: in transgenic mice, an exon 5 knockout model 
showed no functional requirement for this insert, since the mice 
developed normally [5]. 
By contrast, a variety of data point to a profound functional 
importance of the alternative KTS splicing. In fact, mice carrying 
either a KTS-positive or a KTS-negative WT1 transgene, display 
distinct phenotypes, and X-ray crystallographic and structural studies 
along with DNA binding studies indicate that the KTS insertion 
destabilizes the interaction of WT1 with DNA [6,7]. 
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Figure 1. Schematic representation of WT1 mRNA and protein.  
(A) Structure of the WT1 mRNA. WT1 is encoded by ten exons. 
Alternative splicing of exon 5 (splicing 1) and alternative splicing of 
exon 9 (splicing 2) are shown. 
(B) Structure of WT1 protein.  The N-terminal region (exons 1-6) 
comprises a Pro/Gln-rich dimerisation domain (aa 1-180), a 
transcriptional activation (aa 181-250) and repression domain (aa 84-
124), and a putative RNA Recognition Motif (RRM) (aa 11-72), 
encoded by exons 1-6. 
C-terminal region contains  four zinc finger domains, encoded by 
exons 7-10. 
The inclusion of exon 5 leads to an insertion of 17 amino acid 
residues into the N-terminal region of WT1. The splicing 2 in the 
exon 9 leads to the presence or absence of the tripeptide KTS, 
between zinc finger 3 and 4. 
(A: Modified from Biochim.Biophys.Acta (BBA) 2008; 1785:55-62) 
(B: Modified from Trends Biochem Sci. 1998; 23:389-393) 
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Furthermore, some experimental evidence indicate that the 
WT1(+KTS) and WT1(–KTS) variants have different functions: 
WT1(–KTS) isoforms act mainly as transcriptional factors, binding 
GC-rich DNA sequences with high affinity. These variants can work 
as  activators or repressors of a great variety of cellular genes, 
depending on cellular context and cofactor interactions [8]. In 
contrast, WT1(+KTS) isoforms are mainly involved in pre-mRNA 
splicing [9]. Indeed, there is evidence that these variants bind  DNA 
with little affinity, instead showing affinity for RNA [7].  Moreover, 
WT1(+KTS) isoforms are present in nuclear domains rich in splicing 
factors and have been found associated with  proteins involved in 
mRNA-splicing [9]. On the contrary, the WT1(–KTS) isoforms are 
present in diffuse domains of transcriptional activity in the nucleus 
Additionally, since each protein isoform may play specific and 
different biological roles, generation of specific isoform ratio and 
maintenance of this ratio is critical to the overall biological effects of 
WT1 [12]. 
[10,11].  
A new isoform, termed sWT1 due to its small size (35-37 kDa), was 
identified a few years ago. A second promoter, located in intron one, 
generates the mRNA coding for the sWT1 protein, which lacks the 
repression domain found in the N-terminus of the full-length protein. 
The sWT1 was reported to be over-represented in leukemic samples 
and to confer oncogenic properties due to strong activation of certain 
WT1 target genes, as compared to full-length WT1 [13]. 
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Figure 2. Schematic representation of the WT1 major isoforms. 
The blue box represents the exon V; the red box indicates the residue 
KTS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
 
6 
 
1.2  The role of WT1 in leukemia 
       The Wilms’ tumor  gene 1 (WT1) was identified as a tumor 
suppressor gene whose mutations are found associated with urogenital 
disease and the development of Wilms’ tumor, a pediatric kidney 
cancer [1]. In recent years, the study of the involvement of WT1 in 
tumorigenesis has unexpectedly revealed a potential role for WT1 as 
an oncogene [3]. The first evidence supporting this role was the over 
expression of wild-type WT1 in a variety of human cancers of both 
hematological and non-hematological origin [14] (fig.3). Leukemia is 
the most studied of these malignancies and  there is a growing body of 
evidence demonstrating WT1’s biological and clinical importance in 
cell survival, differentiation and proliferation of leukemic cells[14]. 
WT1 gene is highly expressed in the majority of acute myeloid 
leukemias (AML) and acute lymphoid leukemias (ALL) (fig.3). Thus, 
WT1 mRNA and protein serve as promising tumor markers for the 
detection of leukemia and monitoring of disease progression [14-17]. 
In chronic myelogenous leukemia (CML), WT1 levels are usually low 
in the chronic phase but frequently increase in blast crisis phase of the 
disease [15]. In myelodisplastic syndrome (MDS), WT1 mRNA 
expression levels increase along with disease progression [18, 19].  
Eighty percent of the lymphoid leukemias and ninety percent of the 
myeloid leukemias, both adult and childhood, have elevated WT1 
expression [20, 21]. 
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Figure 3. WT1 expression in various types of leukemia and solid 
cancers. Positivity of WT1 overexpression in leukemias and solid 
tumors. AML, acute myeloid leukemias; ALL, acute lymphoid 
leukemias. (From Jpn J.Clin.Oncol. 2010; 40:377-387). 
 
 
 
Elevated levels of WT1 in leukemia are associated with poor response 
to therapy. The majority of AML patients express WT1 at diagnosis 
with frequencies varying from 73-93%, a significant dominance of the 
WT1 (+17AA) isoform and increased amount of WT1 at relapse [22]. 
The expression of WT1 in the majority of human acute leukemias but 
not in normal mononuclear blood cells and normal CD34+ 
hematopoietic progenitors, qualifies the wt1 gene transcript as a 
marker useful in monitoring minimal residual disease (MRD) after 
chemotherapy [23-26].  
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Some reports show no significant correlation between WT1 
expression and different myeloid leukemia FAB subtypes, while there 
are other reports indicating higher WT1 expression in M3 AML, 
harbouring the PML/RARα fusion protein, and less WT1 transcripts 
in M5 AML [27-29]. Thus, a majority of leukemias express high 
levels of WT1 with no strong correlation to phenotype, suggesting that 
WT1 may positively affect proliferation and/or viability of the 
leukemic cells, rather than interfere with specific differentiation 
mechanisms. 
WT1 mRNA levels in bone marrow at diagnosis may be used as a 
predictor of clinical outcome, since several studies show a positive 
correlation between high WT1 expression and a worse long-term 
outcome. Altogether, the positive correlation between WT1 expression 
and poor clinical outcome further support the notion of WT1 as an 
oncogene in leukemia [3]. 
Furthermore, down-regulation of WT1 gene expression in leukemic 
cell lines induces apoptosis indicating that WT1 is important for 
viability of leukemic cells [30]. Moreover, constitutive expression of 
WT1 inhibits apoptosis in K562 leukemic cell line (CML) treated with 
apoptosis inducing agents etoposide, doxorubicin  and  imatinib, 
further supporting that WT1 may antagonize cell death [30-32].  
WT1 is expressed in a small subset of hematopoietic stem cells (1.2%) 
[14]. These results could indicated that WT1-expressing CD34+ cells 
are the normal counterparts of leukemic cells and that leukemic cells 
are mainly generated as a result of leukemic transformation of the 
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WT1 expressing CD34+
 
 cells. Since it is known that progenitor cells 
of various types of tissues express WT1, we may assume that WT1-
expressing  progenitor cells can differentiate into tissue-specific cells 
by down-regulation of WT1 expression, but that if this down-
regulation is impaired, the WT1-expressing progenitor cells continue 
to proliferate and transform into leukemic and solid tumor cells as a 
result of accumulation of secondary, tertiary, or further genetic events 
[14] (Fig.4).  One of the mechanisms at the basis of the involvement 
of WT1 in cancer diseases, is the indirect regulation of programmed 
cell death, through the transcriptional regulation of its target genes 
[33]. 
 
 
       
 
 
Figure 4. WT1 implication in leukemogenesis and tumorigenesis. 
Progenitor cells that express WT1 exist in almost all organs and 
differentiate into organ-specific cells along with down-regulation of 
WT1 expression. When this down-regulation is impaired, the WT1-
expressing progenitor cells continue to proliferate and transform into 
leukemic and solid tumor cells. 
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1.3  Transcriptional regulation of the WT1 target genes 
      As transcription factor, WT1 mediates transcriptional regulation of 
various genes involved in divergent processes as growth, cell cycle 
control, development and apoptosis (Table 1). WT1 can either 
activate or repress transcription of its target genes. Usually, WT1 
target genes are most efficiently trans-activated by the WT1(–KTS) 
isoform of WT1.  
Several genes playing a central role in the control of apoptosis have 
been proposed as targets of WT1, including the pro-apoptotic bcl-2 
family members, Bax and Bak [33-35], bcl-2 itself [36], and the anti-
apoptotic genes A1/Bfl-1 [37]. 
Recently, we identified the anti-apoptotic bag 3 gene, involved in 
apoptosis regulation in leukemia cells, as a novel WT1 target gene 
[38]. We reported that WT1 positively regulates bag3 gene expression 
through a transcriptional mechanism. Moreover, we demonstrated that 
WT1 knockdown affects bag3 expression and enhances apoptosis 
level in the human erythroleukemia cell line K562 [38]. 
The expression of specific bcl-2 family members regulated by WT1 
vary by cell type and by WT1 isoforms. For example, in some cell 
types WT1 promotes apoptosis through up-regulation of pro-apoptotic  
proteins such as Bak and Bax [33-35]. WT1(-17AA/-KTS) up-
regulated transcription of pro-apoptotic gene Bak, inducing apoptosis 
in osteosarcoma cells Saos-2;  on the contrary, the down-regulation of 
the pro-apoptotic Bak gene in K562 cells by over-expression of the 
WT1(+17AA/-KTS) isoform was demonstrated [33, 34]. 
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Table 1. Target genes of WT1. 
 
Target gene Regulation of transcript 
Growth factor receptors  
Epidermal growth factor receptor Repression 
Insulin growth factor I receptor Repression 
Growth factors  
Amphiregulin Activation 
Erythropoietin Activation 
Insuli-like growth factor II Activation 
Connective tissue growth factor Repression 
Transcription factor genes  
Dax-1 Activation 
SRY Activation 
Pou4f2 Activation 
Apoptosis regulators  
A1-Bfl-1 Activation 
Bak Activation/Repression 
Bax Activation 
Bcl-2 Activation/Repression 
Bag3 Activation 
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Cell cycle regulators 
Cyclin E Repression 
c-myc Activation/Repression 
p21 Activation 
Others  
E- cadherin  Activation 
Syndecan-1 Activation 
Nephrin Activation 
Podocalyxin Activation 
Vitamine D Receptor (VDR) Activation 
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In other cell types WT1 inhibits apoptosis and up-regulates anti 
apoptotic target genes such as bcl-2 and A1/Bfl-1. For example, WT1 
(–17AA/–KTS) over-expression results in increased expression of the 
endogenous A1/Bfl-1 gene in murine, hematopoietic, immature 
myeloid 32D cl3 cells [37]. Moreover, WT1 (–17AA/–KTS) activates  
bcl-2 promoter in Saos-2 cells, and suppresses bcl-2 promoter in HeLa 
cells [33]. These different reports with positive and negative effects of 
WT1 on target genes may seem conflicting. However, WT1-mediated 
suppression or activation of target genes is most likely explained by 
different cellular environment, by isoform ratio of WT1variants and 
by physical interactions of WT1 with other cellular proteins. Thus, it 
is possible that the expression of each target gene may be either 
positively or negatively regulated by WT1 [39]. An increasing number 
of interacting partners has been proposed to regulate WT1 
transcriptional function, acting as either co-activators or as co-
repressors (Table 2). These factors include DNA-binding proteins, 
such as members of the p53 family, and proteins that do not directly 
contact DNA, such as Par-4 (Prostate Apoptosis Response factor 4) 
and BASP1 (Brain Acid Solubile Protein) [40-43]. Par-4 can act as 
either a transcriptional co-activator or as a co-repressor for WT1, 
depending on the splice isoform of WT1 [40-41].  
Indeed, Par4 was originally identified as a WT1-interacting protein, 
able to enhance the transcriptional repression by WT1 [40]  This study 
showed that the zinc fingers of WT1 mediated the interaction with 
Par4. Another study demonstrated the presence of an independent 
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binding site within WT1 for Par4, the 17AA motif present in only 
specific splice isoforms of WT1. Par4 was able to act as a co-activator 
for this splice isoform–specific transcriptional  domain [41]. Thus, 
Par4 can mediate both positive and negative interactions with WT1 
via these domains that lead to either transcriptional activation or 
repression. BASP1 was identified as a WT1 transcriptional co-
suppressor. It interacts with the repression domain of WT1, inhibiting 
the WT1 transcriptional regulation on target genes in podocyte cells. 
[42] Recently, we identified a novel human WT1 cofactor, the 
Krüppel-like zinc finger protein, ZNF224, and demonstrated that 
ZNF224 may act as a transcriptional co-regulator of WT1 in order to 
modulate WT1 transcriptional activity on apoptotic target genes [44]. 
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Table 2. WT1 binding proteins. 
 
PROTEIN WT1-INTERACTING 
DOMAIN 
REMARKS 
WT1 N-terminus (1-180aa) Dominant negative function of 
WT1 mutants 
Hsp70 N-terminus (1-180aa) Decreased proliferation 
hUBC9 N-terminus (85-179aa) Involved in sumoylation of WT1 
BASP1 N-terminus (71-101aa) WT1 transcriptional co-
suppressor 
Pax-2 N-terminus (1-466 aa) Joint co-expression in renal 
development 
Par-4 N-terminus (+17AA) Involved in apoptosis/coactivator 
with WT1(+17AA)  
 ZN-fingers Induces WT1 TR 
STAT3 N-terminus (1-281aa) Promotes cell proliferation 
U2AF65 ZN-fingers Role in pre-mRNA splicing 
Ciao 1 
 
ZN-fingers Reduces WT1 TA on EGF 
receptor 
ZNF255 ZN-fingers  Reduces WT1 TA 
p53 ZN-fingers Repress the WT1 TA 
P73 ZN-fingers Ihibits DNA-binding and TA of 
WT1 
CBP ZN-fingers Induces WT1 TA 
SRY ZN-fingers WT1 nad SRY acts 
synergistically to activate 
transcription 
E1B55K ZN-fingers Inhibits WT1-mediated cell 
death 
ZNF224 ZN-fingers Enhances activation mediated by 
WT1 on pro-apoptotic genes and 
inhibiting WT1-mediated 
transcriptional activation of anti-
apoptotic genes. 
 
 
The abbreviations used; TA, transcriptional activation; TR, 
transcriptional repression; ZN-fingers, Zinc fingers; Hsp70, Heat 
shock protein 70; Par-4, Prostate apoptosis respone 4; UBC9, 
Ubiquitin-conjugating enzyme 9; BASP1, Brain acid soluble protein 
1; CBP, CREB binding factor. 
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1.4 The zinc-finger protein ZNF224 
        ZNF224 is a member of the KRAB Zinc-Finger family of 
transcription factor [45].  The Zinc Finger Protein family (ZFP), is one 
of the main groups of proteins with DNA-binding activity. One third 
of ZFPs, the KRAB-ZFPs, contain a potent transcriptional repression 
domain defined as the Kruppel-associated box (KRAB). The KRAB-
ZFPs are mostly localized in the nucleus and work as repressors of 
transcription mediated by RNA polymerases I, II and III.  Although 
the function of KRAB-ZFPs is largely unknown, they appear to play 
important roles in controlling cell differentiation, apoptosis, and 
cancer.  
The ZNF224 protein consists of 707 aminoacids, contains 19 
tandemly repeated C2H2 zinc finger domains at the C-terminal region, 
and at the NH2 terminus ZNF224 contains a KRAB repression 
domain of 45 aminoacids [45] (fig.5).  
 
 
 
 
 
 
Figure 5. Schematic representation of ZNF224. ZNF224 protein 
contains 19 tandemly repeated C2H2 zinc finger domains at the C-
terminal region and a KRAB repression domain of 45 aminoacids at 
the NH2 terminus. 
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ZNF224 is ubiquitously expressed in several human adult and fetal 
tissues, albeit with quantitative differences [46]. 
The human aldolase A was the first gene identified as target of  
ZNF224 transcriptional repression [47,48]. To repress gene 
transcription, ZNF224  recruits, through its KRAB domain, the KAP-1 
corepressor and enzymes activities, in accordance with repression 
mechanism of KRAB-ZFP family [46]. Recently, the arginine 
methyltransferase PRMT5, was demonstrated to play  a crucial role in 
the transcriptional ZNF224 repressor complex [49].  
Subsequently, the mitochondrial carrier citrate gene was indicated as a 
target of ZNF224-mediated transcriptional repression [50]. The 
finding that the two so-far-known target genes of ZNF224 repressor 
activity (aldolase A and the mitochondrial carrier citrate) both encode 
proteins involved in carbohydrate oxidation in humans leads to 
suppose a role for ZNF224 in controlling the energy metabolism. 
An alternatively spliced isoform arising from the ZNF224 gene, 
namely ZNF255, was identified. ZNF255, shows a different 
expression pattern in human tissues, a distinctive subcellular 
localization and a reduced repression activity compared with ZNF224 
[46]. These distinctive feartures might indicate a divergent function of 
ZNF224 and ZNF255. This suggestion was strengthened by the 
identification of specific interaction between ZNF224 or ZNF255 and 
WT1 splice variants (-KTS) and (+KTS). We demonstrated a specific 
nuclear interaction of ZNF224 with the (–KTS) transcriptional 
isoform. On the contrary, ZNF255 interacts preferentially with the 
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+KTS isoform, colocalizes with WT1 in translating ribosomes and is 
present in ribonuclear protein complexes (RNP), strongly indicating a 
role for this interaction in post-transcriptional control [44]. 
The interaction ZNF224/WT1(-KTS) was involved in the 
transcriptional regulation as demonstrated by co-transfection and ChIP 
experiments using a known WT1 target gene, the vitamin D receptor 
(VDR). These findings indicate that ZNF224 acts as a transcriptional 
co-activator of WT1 on VDR promoter, providing the first example of 
a KRAB-ZPF protein that does not act simply as a transcriptional 
repressor. In addition, siRNA-mediated knockdown of ZNF224 in the 
human erythroleukemia cell line K562 resulted in a decreased 
expression of VDR [44]. Since it is known that vitamin D can induce 
apoptosis in leukemia cells [51], our finding suggests a role for 
ZNF224/WT1 interaction in this pathway through the transcriptional 
activation of VDR. 
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1.5 Aim of the work 
        Recently, we demonstrated that the zinc-finger protein ZNF224 
is a novel transcriptional cofactor of WT1(-KTS) isoform [44]. 
According to the evidence that both WT1(-KTS) and ZNF224 are 
transcriptional factors, we reported their specific nuclear interaction 
and demonstrated that this interaction results in an increase of 
transcriptional activation mediated by WT1 on vitamin D receptor 
promoter (VDR). VDR, a known target of the WT1 transcriptional 
activation, elicits anti-tumor effects mainly through the induction of 
cancer cell apoptosis and cell cycle arrest. We demonstrated that 
ZNF224 acts as a co-activator of WT1 in order to modulate VDR 
transcription in chronic myeloid leukemia K562  cell line [44]. 
The aim of this thesis  was to identify other genes potentially 
regulated by the WT1/ZNF224 interaction and to clarify the role of 
this interaction in the control of apoptosis in leukemic cells. In 
particular, we decided to analyze the consequences of this interaction 
on WT1-dependent transcriptional regulation of pro-apoptotic genes 
Bax and Bak, and anti-apoptotic genes A1/Bfl-1 and bag3 in K562 
cell line.  In fact, it is known that WT1 exerts its antiapoptotic effects, 
at least partially, through the regulation of expression of  the bcl-2 
family members [34]. Our results demonstrated that ZNF224 acts in 
fine tuning of WT1-dependent control of apoptotic gene expression.  
These findings prompted us to investigate if ZNF224 itself could be 
modulated by chemioterapeutic agents, in order to clarify its role in 
apoptosis regulation.   
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The study of the role of the proteins WT1 and ZNF224 in regulation 
of apoptotic genes expression  and in apoptosis in leukemic cells, will 
provide novel insight into the understanding  the molecular 
mechanism by which these proteins are involved in the apoptosis 
regulation,  paving the way to new potential strategies for the 
treatment of leukemia 
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2. Materials and methods  
 
2.1 Cell culture and stable transfection 
        HEK293 human cell line were cultured in Dulbecco’s modified 
Eagle’s medium (Bio-Whittaker, Verviers, Belgium) supplemented 
with 10% fetal calf serum, 100 µg/ml streptomycin-penicillin mix 
(Bio-Whittaker) at 37°C in 5% CO2. The stable clone from HEK293 
expressing p3XFLAG-ZNF224 (CL13) and clone from HEK293 cells 
transfected with empty p3XFLAG (CN2), were obtained as described 
[49]. 
The chronic myeloid leukemia cell lines K562, MEG-01, and acute 
myeloid leukemia cell lines HEL, JK1, PLB989, KG1, PL21, HL60 
and NB4, were cultured in RPMI 1640 supplemented with 10% fetal 
calf serum and 100 µg/ml penicillin-streptomycin mix (Bio-
Whittaker) at 37°C in 5% CO2. Acute myeloid leukemia cell lines 
F36-P and UT7 were cultured in RPMI 1640 containing 40ng/ml GM-
CSF, supplemented with 10% fetal calf serum and 100 µg/ml 
penicillin-streptomycin mix (Bio-Whittaker) at 37°C in 5% CO2. To 
obtain pools of clones stably expressing 3XFLAG-ZNF224, K562 
cells were transfected with p3XFLAG-ZNF224 G418-selectable 
plasmid using HiPerFect Reagent (Qiagen, Hilden, Germany). 
Transfected cells were selected in medium containing 800 µg/ml 
G418 (Promega, Madison, WI) for 4 weeks. Dead cells were removed 
by Ficoll density gradient centrifugation (GE Healthcare Bio Science 
AB, Sweden, Uppsala). The positive pool of clones were analyzed by 
Western Blotting using M2 anti-FLAG antibody (Sigma-Aldrich, MO, 
Materials and methods 
 
 
22 
 
USA). As negative control we selected pools of K562 cells stably 
transfected with the empty p3XFLAG G418-selectable plasmid.  
We used pool of K562 cells transduced with a retroviral vector 
encoding for WT1(-KTS) or with the control empty vector (pMIG), as 
described [52].  
 
 
2.2 Isolation of CD34+ cells from umbilical cord blood 
        Umbilical cord blood was, after ethical approval and informed 
consent, collected from mothers giving birth to normal full-term 
infants, from which mononuclear cells were isolated by separation on 
Lymphoprep (Nycomed Pharma, Oslo, Norway); CD34+ cells were 
enriched by labeling with magnetic beads (CD34 Progenitor Cell 
Isolation Kit, Miltenyi Biotec, Bergisch-Gladbach, Germany) 
according to the manufacturer’s instructions. CD34+ cell purity was 
always >90% as determined by flow cytometry. CD34+ cells were 
cultured in StemSpan medium (StemCell Tech) supplemented with 
20% fetal calf serum containing 100ng/ml SCF, 100ng/ml flt3-ligand, 
100ng/mnl TPO.  
 
 
2.3 ShRNA mediated knockdown  
        To obtain stable ZNF224 gene silencing (clone C3.3), we 
transfected 2x106 HEK293 cells with 10 µg of short interfering RNA 
plasmid SH2351C3 (ZNF224 shRNA) (Open Biosystems, Huntsville, 
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Alabama, USA), using Lipofectamine Reagent (Invitrogen, Carlsbad, 
CA, USA), according to the manifacturer’s protocol. The cells were 
grown in selective medium until colony formation. Positive clones 
were analyzed by western blotting using anti-ZNF224 antibody (T3). 
Pools of K562 clones silenced for ZNF224 (ZNF224 shRNA) were 
obtained by transfection of 1.5 µg of short interfering RNA plasmid 
SH2351C3 (Open Biosystem) using the HiPerFect Reagent (Qiagen), 
according to the manifacturer’s protocol; transfection of a non-
silencing shRNA (scrambled shRNA) was used as negative control 
(Open Biosystem). Transfected cells were selected in medium 
containing 500 µg/ml Puromycin (Promega) for 4 weeks. Dead cells 
were removed by Ficoll density gradient centrifugation (GE 
Healthcare). Positive clones were analyzed by western blotting using 
anti-ZNF224 antibody (T3). 
K562 cells were transiently transfected using the HiPerFect Reagent 
(Qiagen) in 12-well plates with 1.5 µg of the short interfering RNA 
plasmid SH2351C3 to silence ZNF224, or 1.5 µg of the short 
interfering RNA plasmid SH25dE-10 to silence WT1, or 1.5 µg of 
non-silencing negative control (scrambled shRNA). All plasmids were 
purchased from Open Biosystems. Cells were collected 48h after 
transfection.   
 
 
2.4 RNA isolation, reverse transcription and  real-time PCR 
        Total RNA was isolated using TRIzol Reagent (Invitrogen, 
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Carlsbad, CA, USA), according to the manifacturer’s protocol. 1µg of 
each RNA was reverse transcripted using QuantiTect Reverse 
Transcription Kit (Qiagen), according to the manifacturer’s protocol. 
Real-time PCR was carried out in a iCycler Thermal Cycler (Bio-Rad, 
Berkeley, CA, USA) using the SYBR Green I Master Mix (Bio-Rad) 
and specific primers for: ZNF224 (Fw 5’-gggctgtcttggcacaattc-3’, Rev 
5’-ttgcctccttgaacgtggtc-3’); WT1 (Fw 5’-gtgaaaccattccagtgtaaaac-3’, 
Rev 5’-gccaccgacagctgaagggc-3’); bag3 (Fw 5’-cctgttagctgtggttg-3’, 
Rev 5’-aacatacagatattcctatggc-3’); VDR (Fw 5’-tccagttcgtgtgaatgatg-
3’, Rev 5’-gaagattcagatgacccttc-3’); A1/Bfl-1 (Fw 5’-
cggcatcattaactggggaag-3’, Rev 5’-ctagaagttacaggaaagatc-3’); Bak (Fw 
5’-tgaaaaatggcttcggggcaa-3’, Rev 5’-ctctcaaacggctggtggcaatc-3’); Bax 
(Fw 5’-tcaggatgcgtccaccaagaaag-3’, Rev 5’-
gcaaagtagaaaagggcgacaacc-3’); matrin3 (Fw 5’-
cattctaataaggagtggagtc-3’, Rev 5’-tgctagtttccactctgcctt-3’); aldolase A 
(Fw 5’-tcaaccacactccgtccacg-3’, Rev 5’-gtagcaagttccggtgcttc-3’); -
actin (Fw 5’-cgacaggatgcagaaggaga-3’, Rev 5’-
cgtcatactcctgcttgcttgctg-3’). β-actin house-keeping gene was used as a 
reference gene for relative quantification. All real-time PCR reactions 
were performed in triplicates. 
To analyze the expression of ZNF224 mRNA levels in K562 cells 
treated with ara-C and in the untreated controls, total RNA was 
isolated using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s protocol. 0.5µg of total RNA was reverse transcribed 
using High-Capacity cDNA Reverse Transcription Kit (Applied 
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Biosystems Inc., Foster City, CA, USA) with random hexamer 
primers according to the manufacturer’s instructions. Quantitative 
PCR was carried out using TaqMan probe-based chemistry (Applied 
Biosystems); the probe for ZNF224 (Hs00273760) and the 
endogenous control β-actin (Hs99999903_m1) were purchased as 
Assay-on-Demand (Applied Biosystems). The amplification reactions 
were all performed in duplicates in an ABI Prism 7000 Sequence 
Detection System (Applied Biosystems). Data were collected and 
analyzed using the Sequence Detector v.1.1 software (Applied 
Biosystems).  
The relative quantification in gene expression was determined using 
the ∆∆CT method [53]. Normalization: ∆CT= CT (sample)-CT 
(endogenous control); ∆∆CT= ∆CT (sample1)-∆CT (sample2). Relative 
quantification= 2-∆∆CT. Efficacy of the PCR amplification of controls 
and test was identical; parallelism of standard curves of the control 
and test was confirmed. 
P-value was determined by Student’s t test. All P values were 
considered significant when P<0.05. 
 
 
2.5 Transient transfection and luciferase-reporter assays 
       The HEK293 stable clones CL13, CN2 and C3.3 were transiently 
transfected using Lipofectamine Reagent (Invitrogen) in 12-well 
plates with 0.2 µg of a luciferase reporter plasmid containing the 
proximal bag3 promoter (PromBag3-Luc) and 0.4, 0.8 and 1.2 µg of 
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WT1(-KTS) expression plasmid. The pGL4-null empty vector (0.2 
µg) was used to evaluate the background luciferase activity, whereas 
the pCMV-LUC (50ng) was the positive control for the assay. To 
normalize the luciferase assay a pRL-CMV plasmid (20ng) coding for 
the renilla luciferase was used. The Dual-Luciferase Reporter Assay 
System (Promega Corporation, WI, USA) was performed 48h after the 
transfection according to manufacturer’s instructions. Results are 
representative of two independent experiments. 
 
 
2.6 Western blot analysis 
       Total protein extract was obtained as follow: cells were washed 
twice with cold PBS, then were lysed in lysis buffer (10 mM Hepes 
pH 7.8,  250 mM NaCl, 5 mM EDTA pH 8.0, 1% Nonidet P-40, 1 
mM sodium orthovanadate and 50 mM sodium fluoride) and protease 
inhibitors (1mM phenylmethylsulfonyl fluoride (PMSF), 1µg/ml 
aprotinin and 1µg/ml pepstatin A)  for 30 min on ice. The extract was 
centrifuged in a microfuge at maximum speed for 10 min and the 
supernatant was quantified using the Bio-Rad protein assay reagent, 
resolved on SDS–PAGE and then transferred to Hybond membranes 
(Amersham Biosciences, NJ, USA). Non-specific binding sites were 
blocked for  2h  with 5% milk in Tris-Tween buffered saline  (tTBS)  
(5 mM Tris pH 7.5, 15 mM NaCl, 0.1% Tween-20), washed three 
times with tTBS and incubated with the following antibodies: 
anti-FLAG (M2) from Sigma-Aldrich, 1:1000 
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anti-VDR (D-6) from Santa Cruz Biotechnology, 1:500 
anti-GAPDH (7-B) from Santa Cruz Biotechnology, 1:1000 
anti-BAX (B-9) from Santa Cruz Biotechnology, 1:500 
For these primary antibodies the secondary antibody was goat-anti-
mouse IgG (H+L)-HRP conjugated (BioRad170-6516) antibody, 
1:3000, detected with an ECL western blot detection system 
(Amersham Biosciences). 
anti-WT1 (C19) from Santa Cruz Biotecnology, 1:500 
anti-BAG3 (TOS-2) from BioUniverSa s.r.l., Fisciano, Italy,  1:10000 
anti-A1/BFL-1 (PRS3873) from Sigma-Aldrich, 1:1000 
anti-Cleaved caspase-3 (Asp175) from Cell Signaling, Denvers, USA, 
1:1000 
anti-BAK (B5897) from Sigma-Aldrich, 1:2000 
For these primary antibodies the secondary antibody was goat-anti-
rabbit IgG (H+L)-HRP conjugated (BioRad170-6515) antibody, 
1:3000, detected with an ECL western blot detection system 
(Amersham Biosciences). 
The Western blot for ZNF224 was performed using the anti-ZNF224 
(T3) antibody (Rabbit polyclonal antibody) [47].  Non-specific 
binding sites were blocked for 2h in SuperBlock blocking solution 
buffer in PBS (Thermo Scientific) with 0.1% Tween-20. SuperBlock 
blocking solution buffer was used in incubation steps with primary 
and secondary antibody. The primary antibody was diluted in a ratio 
1:500.  
The secondary antibody was Goat-anti-rabbit IgG (H+L)-HRP 
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conjugated (BioRad170-6515) antibody (1:3000), detected with an 
ECL western blot detection system (Amersham Biosciences). 
 
 
2.7 Chromatin Immunoprecipitation (ChIP) assay 
       The ChIP assay was performed as previously described [49]. 
Briefly, cross-linked chromatin was prepared from HEK293 cells 
transfected with 3XFLAG-CMV-7.1-ZNF224 or pcDNA3WT1(-
KTS), or co-transfected with 3XFLAG-CMV-7.1-ZNF224 and 
pcDNA3WT1(-KTS). Briefly, 5x107 cells were cross-linked with 1% 
of fixing solution (11% HCHO, 100 mM NaCl, 1 mM EDTA, 0.5 mM 
EGTA, 50 mM Hepes pH 8.0) and harvested in 1.5 ml of cell lysis 
buffer (5 mM PIPES pH 8.0,  85 mM KCl,  0.5% Nonidet P-40) with 
protease inhibitors (1mM phenylmethylsulfonyl fluoride (PMSF), 
1µg/ml aprotinin and 1µg/ml pepstatin A). Nuclei were collected and 
resuspended in 300 µl of nuclear lysis buffer (50 mM Tris-HCl pH 
8.0, 10 mM EDTA, 0.8% SDS, and protease inhibitors). The DNA 
was sheared by sonication to an average length between 200 and 1000 
base pairs. Sonicated DNA was diluted 3-fold in dilution buffer (10 
mM Tris-HCl, pH 8.0, 0.5 mM EGTA, 1% Triton X-100, 140 mM 
NaCl, protease inhibitors) and precleared with protein A/G plus-
agarose (Santa Cruz Biotechnology) at 4°C for 1h. The precleared 
extract obtained from cells transfected with 3XFLAG-CMV-7.1-
ZNF224 or co-transfected with 3XFLAG-CMV-7.1-ZNF224 and 
pcDNA3WT1(-KTS) was divided in two aliquots. One aliquot was 
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incubated with 3µg of FLAG M2 mouse antibody (Sigma-Aldrich), 
and the other was incubated with 3µg of anti-mouse IgG  (Sigma-
Aldrich), used as control. The precleared extract obtained from cells 
transfected with pcDNA3WT1(-KTS) was divided in two aliquots and 
incubated with 5µg of rabbit anti-WT1 antibody (C19 Santa Cruz 
Biotechnology), or with 5 µg of anti-rabbit IgG (Sigma-Aldrich), used 
as control. Beads were collected by centrifugation and then washed 
three times with washing buffer P1 (30mM NaCl, 50mM Tris-HCl pH 
8.0, 1mM EDTA, 10% glycerol, 0.1% Nonidet P-40, protease 
inhibitors), twice with washing buffer  P2 (50Mm Tris-HCl pH 8.0, 
150 mM NaCl, 1mM EDTA, 10% glycerol, 0.1% Nonidet P-40, 
protease inhibitors) and twice with TE buffer (1mM Na-EDTA, 
10mM Tris-HCl pH8.0). The first supernatant of the IgG control 
served as the total input control for the PCR analysis effectiveness. 
The beads were taken up in 100 µl of TE.  1 µg of RNase was added, 
and cross-links were reversed at 65°C overnight. The next day, 
samples were adjusted to 0.5% SDS and 0.5 mg/ml proteinase K and 
incubated for 3h at 50°C. DNA was purified by phenol-chloroform 
extraction. ChIP samples were then analyzed by PCR using 2µl of 
immunoprecipitated material, the input control diluted in a ratio 1:200, 
and specific primers for: Bax  (Fw 5’-agatgctcattggacagtcacg-3’, Rev 
5’-gagtttctgcccctcagtgct-3’); Bak (Fw 5’-gatggagtcttgcactgtcacc-3’, 
Rev 5’-ttctggctaacatggtgaaacc-3’); bag3 (Fw 5’-agtccagctcgtccggcttc-
3’, Rev 5’-ggccagttgctacctccct-3’); A1/Bfl-1 primer sequences are 
described in [37].  Aldolase A primer sequences are described in [48]; 
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as control of immunoprecipitated chromatin specificity, PCR was 
performed using G3PDH primers (Fw 5’-ggtcgtattgggcgcctggtcacca-
3’, Rev 5’-cacacccatgacgaacatgggggc-3’). Results are representative 
of two independent experiments. 
 
 2.8 Analysis of viability and apoptosis by flow cytometry  
        Apoptosis of  K562 cells, pools of K562 cells stably 
overexpressing ZNF224 (ZNF224-FLAG) or stably transfected with 
ZNF224 shRNA, pool of K562 cells retrovirally transduced for WT1(-
KTS), was induced by cytosine arabinoside (ara-C) (Sigma-Aldrich). 
To this aim, cell number was counted in a Bürker chamber and 
viability was determined by trypan blue exclusion.  For assessment of 
apoptosis, cells were plated at a density of 2.5x105/well in 12-well 
plates and were stained with propidium iodide (Sigma-Aldrich) and 
analyzed by flow cytometry as described [54].  
For annexin V staining, 3x105 cells were rinsed twice in cold PBS 
containing Ca2+ and Mg2+, than were resuspended in cold annexin V-
binding buffer (5M NaCl, 1M CaCl2, 1M Hepes buffer/NaOH pH 7.4) 
and stained with Annexin V-APC (550474, BD Pharmingen) and 
DAPI (4’,6-diamidino-2-phenylindole) (D9564, Sigma-Aldrich). This 
allows for the discrimination of live cells (DAPI impermeable) from 
apoptotic cells (annexin V and DAPI positive cells). Following 
incubation on shaker in the dark for 15 min at 4°C, cells were 
analyzed on a FACS Aria flow cytometer (BD Biosciences 
Immunocytometry System). 
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3.RESULTS  
 
3.1 ZNF224 represses WT1-mediated bag3 expression 
        We recently reported a specific nuclear interaction between 
ZNF224 and WT1 and demonstrated that this interaction enhances 
WT1-mediated trans-activation of VDR promoter, thus implying that 
ZNF224 acts as a transcriptional co-regulator of WT1 [44].   
In this work we investigated if ZNF224 also affects WT1-dependent 
transcriptional regulation of the anti-apoptotic bag3 gene expression, 
recently identified as a novel target of WT1 [38]. To this aim we used 
a HEK293 cell clone, which does not express endogenous WT1, while 
stably expressing ZNF224 (CL13 clone) [49] and a C3.3 clone stably 
expressing a small hairpin RNA (shRNA) specific for ZNF224. As 
control, we used a clone generated by stable transfection of HEK293 
cells with the empty vector (CN2 clone) [49]. The expression level of 
ZNF224 in these clones is shown in figure 6A. CN2, CL13 and C3.3 
clones were transfected with increasing amounts of the WT1(-KTS) 
expression vector  and bag3 expression was evaluated at mRNA and 
protein levels by quantitative real-time-PCR and western blot 
analyses, respectively. A progressive increase in bag3 mRNA and 
protein levels was observed in CN2 clone (Fig.6B lanes 1, 4, 7 and 
Fig.6C left panel), thus confirming that WT1 activates bag3 gene 
expression [38]. Conversely, in CL13 clone, overexpression of 
ZNF224 considerably abolished WT1-mediated bag3 induction, as 
indicated by down-modulation of bag3 transcript and protein 
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expression (Fig.6B lanes 2, 5, 8 and Fig.6C middle panel). In C3.3 
clone, silenced for ZNF224, the increase in bag3 mRNA and protein 
was higher than in CN2 clone (Fig.6B lanes 3, 6, 9 and Fig.6C right 
panel), thus indicating an increased transactivation of WT1 on bag3 
gene in the absence of ZNF224.  
To further investigate the effects of ZNF224 on bag3 gene 
transcription, we introduced a luciferase reporter plasmid containing 
bag3 gene promoter into CN2, CL13 and C3.3 clones, in presence of 
increasing amounts of WT1(-KTS) expression plasmid.  Analysis of 
luciferase activity shows that WT1 was able to activate bag3 promoter 
in a dose-dependent manner in CN2 (Fig.7B lanes 10, 13, 16) as 
opposed to CL13 (Fig.7B lanes 11, 14, 17), in which we observed a 
dose-dependent decrease of WT1-mediated transcriptional activity. As 
expected, in C3.3 clone an increased luciferase activity with respect to 
CN2 clone (Fig.7B lanes 12, 15, 18 versus lanes 10, 13, 16) was 
observed. These findings indicate that ZNF224 suppresses bag3 gene 
expression by a transcriptional mechanism. 
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Figure 6. ZNF224 overexpression negatively regulates WT1-
mediated  bag3 expression.  (A) Western blot analysis of the 
ZNF224 protein level in CL13, CN2 and C3.3 HEK293 clones, using 
anti-ZNF224 antibody (T3). G3PDH is shown as equal loading 
control. Molecular weight to the left. (B) RT-qPCR analysis of the 
bag3 mRNA expression in CN2, CL13 and C3.3 clones transiently 
transfected for 48h with increasing amount of WT1(-KTS) expression 
vector. mRNA levels of untransfected clones were referred to as 1 
(lanes 1-3). Error bars represent standard deviations of three 
independent experiments. *P<0.05 versus control.  (C) Western blot 
analysis of BAG3 and WT1 protein levels in total protein lysates 
obtained from CN2, CL13 and C3.3 clones transiently transfected with 
increasing amount of WT1(-KTS) expression vector for 48h. G3PDH 
was used to monitor equal loading conditions. One representative 
result out of three performed is presented. Molecular weight to the 
left. 
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Figure 7: ZNF224 suppresses WT1-mediated transcriptional 
activation of bag3 promoter. (A) Schematic representation of the 
reporter plasmid containing the bag3 promoter region (-1278 to +1) and 
of the WT1(-KTS) expression vector containing the illustrated region 
(+400 to +1680) used in transient  transfection experiments. (B) CN2, 
CL13 and C3.3 HEK293 clones were co-transfected with prom-bag3 
reporter and increasing amount of WT1(-KTS) expression vector (lanes 
10-18) or trasfected with prom-bag3 alone as control (lanes 7-9). After 
48h cells were collected and relative luciferase activities were 
calculated, with the activity of control cells set as 1 (lanes 7-9) 
(triplicate determinations). The effect of WT1 on bag3 promoter in 
CN2, CL13 and C3.3 clones is shown. pGL4-null empty vector activity 
indicates the background (lanes 4-6) and pCMV-LUC was the positive 
control (lanes 1-3). Error bars represent standard deviations of three 
independent experiments. (C) WT1(-KTS) protein overexpression was 
evaluated by western blot analysis. G3PDH was used as loading 
control. Molecular weight to the left. 
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3.2 ZNF224/WT1 interaction modulates the expression of apoptosis-
regulating genes in K562 cells 
      To further confirm that WT1/ZNF224 complex modulates bag3 
expression and to better characterize its role in leukemic cells, we 
evaluated the effects of the knockdown of ZNF224 on the expression 
of WT1 target genes. To this aim, K562 cells were transfected with 
two different shRNA plasmids targeting ZNF224 and a negative 
control shRNA. The knockdown of ZNF224 leads to a dramatic 
increase in bag3 and A1/Bfl1 anti-apoptotic mRNAs expression, 
whereas it causes a decrease in Bak and Bax mRNAs expression, as 
already previously observed for VDR [44], another pro-apoptotic 
WT1 target gene [51] (Fig.8A). The aldolase A mRNA was used as 
control, being known the role of transcriptional repression exerted by 
ZNF224 on aldolase A gene transcription [47,48]; as expected, 
ZNF224 silencing produced a considerable increase in aldolase A 
mRNA expression (Fig.8A). The changes observed in mRNAs 
expression after ZNF224 RNAi were confirmed at the protein levels 
by western blotting (Fig.8B). To further verify that ZNF224, besides 
its role as transcriptional repressor, may act as a cofactor of WT1, we 
generated a pool of K562 cells stably transfected with ZNF224 
(Fig.9A) and evaluated the mRNA levels of WT1 target genes. As 
shown in Fig.9C, ZNF224 overexpression is accompanied by a 
decrease in bag3 and A1/Bfl1 mRNAs expression and an increase in 
Bak, Bax and VDR mRNAs expression. The decrease in aldolase A 
mRNA expression was used as a control of ZNF224 overexpression 
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(Fig.9C). We next confirmed that the ZNF224-mediated modulation 
of apoptotic genes was dependent on WT1 expression in K562 cells. 
To this aim we transiently transfected a pool of K562 cells over-
expressing ZNF224 with WT1 shRNA plasmid (Fig.9B). The 
depletion of WT1 in this pool of cells affects the apoptotic gene 
expression, demonstrating that ZNF224 requires WT1 to modulate the 
expression of bag3, A1/Bfl1, Bax, Bak and VDR (Fig.9C). On the 
other hand, the expression of aldolase A, a direct target of ZNF224 
transcriptional repression, was not influenced by WT1 knock-down 
(Fig.9C). The above reported experiments indicate that ZNF224 
cooperates with WT1 in the transcriptional modulation of apoptosis-
regulating genes, enhancing gene activation mediated by WT1 on pro-
apoptotic genes and inhibiting WT1-mediated transcriptional 
activation of anti-apoptotic genes. 
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Figure 8: ZNF224 depletion in K562 cells affects the expression of 
WT1 target genes. (A) RT-qPCR analysis of mRNA levels in K562 
cells transfected for 48h with two different ZNF224 shRNAs (shRNA 
C3 and shRNA E7.3) or non silencing scrambled shRNA, as negative 
control. Error bars represent standard deviations of three independent 
experiments. *P=0.05 versus scrambled shRNA; **P<0.002 versus 
scrambled shRNA; ns, not significant. (B) Total protein extracts were 
analyzed by western blot with the indicated antibodies. G3PDH was 
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used to monitor equal loading conditions. One representative result 
out of three performed is presented. Molecular weight to the left. 
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Figure 9: ZNF224 and WT1 cooperate in the modulation of 
apoptotis-regulating genes. (A) Western blot analysis showing the 
expression of ZNF224-FLAG protein in pool of K562 cells stably 
transfected with the expression vector p3XFLAG-ZNF224 (+) or with 
p3XFLAG empty vector used as control (-). G3PDH was used to 
monitor equal loading conditions. Molecular weight to the left. (B) 
Western blot analysis of WT1 protein level in pool of K562 cells 
stably transfected with the expression vector p3XFLAG-ZNF224 and 
transiently transfected with WT1 shRNA (+) or with non silencing 
scrambled shRNA used as control (-). G3PDH was used to monitor 
equal loading conditions. Molecular weight to the left. (C) RT-qPCR 
analysis of mRNA levels in pool of K562 cells over-expressing 
ZNF224 (pool ZNF224-FLAG), or in pool of K562 cells over-
expressing ZNF224 and transiently transfected with WT1 shRNA 
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(pool ZNF224-FLAG + WT1 shRNA). The empty vector used as 
control was: pool of K562 stably transfected with p3XFLAG for the 
pool ZNF224-FLAG; pool of K562 cells over-expressing ZNF224 and 
transiently transfected with scrambled shRNA for the pool ZNF224-
FLAG + WT1 shRNA. Error bars represent standard deviations of 
three independent experiments. *P<0.05 versus control; **P=0.004 
versus control; ns: not significant.  
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3.3 WT1 recruits ZNF224 to the promoter of apoptosis-regulating 
genes 
       To determine whether WT1 recruits ZNF224 on endogenous 
WT1 target genes we performed chromatin immunoprecipitation 
(ChIP) experiments. HEK293 cells were transfected with an 
expression vector for ZNF224 (p3xFLAG-ZNF224)  (Fig.10A), or an 
expression vector for WT1 (pcDNA3WT1(-KTS) (Fig.10B), or co-
transfected with pcDNA3WT1(-KTS) and p3xFLAG-ZNF224 
(Fig.10C) and chromatin was immunoprecipitated with FLAG 
(fig.10A and C) or with WT1 antibodies (Fig.10B). As expected, we 
observed by PCR analysis that ZNF224 was bound to the aldolase A 
gene promoter (AldA) and not to the promoter regions of WT1 target 
genes (Fig.10A), thus indicating that ZNF224 alone was unable to 
directly bind to these WT1 target promoters; furthermore, WT1 was 
bound to Bax, Bak, A1/Bfl1 and bag3 promoter regions and not to 
AldA (Fig.10B). When ZNF224 was over-expressed along with WT1, 
it bound WT1 target gene promoters, thus demonstrating that WT1 
recruits ZNF224 on these promoters (Fig.10C). No bands were 
observed when a G3PDH fragment was amplified, using the same 
chromatin samples immunoprecipitated with FLAG (fig.10A, C) or 
with WT1 antibodies (Fig.10B), thus demonstrating the specificity of 
chromatin immunoprecipitation.  
This result provides experimental evidence that WT1 and ZNF224 
interact at chromatin level and this interaction does not involve direct 
DNA binding of ZNF224.  
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Figure 10: ZNF224 is recruited by WT1 to apoptotic target gene 
promoters. Chromatin immunoprecipitation assay was performed with 
anti-FLAG antibody (panel A and C) or anti-WT1 antibody (panel B). 
Immunoprecipitation with non-specific IgG were used as negative 
control. Non-immunoprecipitated chromatin was used as total input 
control. PCR analysis was used to evaluate the WT1 and ZNF224 
binding to AldA, A1/Bfl-1, bag3, Bax and Bak promoter regions, using 
specific primers. As control of specificity of immunoprecipitated 
chromatin, PCR was performed using G3PDH primers. Results are 
representative of two independent experiments. Size, in base pairs, of 
the PCR products to the left. (D) Total protein extracts from HEK293 
transfected with p3XFLAG-ZNF224 and from HEK293 co-transfected 
with p3XFLAG-ZNF224/pcDNA3WT1(-KTS) were analyzed by 
western blot with the indicated antibodies. G3PDH was used to monitor 
equal loading conditions. Molecular weight to the left. 
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3.4  ZNF224  and WT1 expression in myeloid leukemia cell lines 
        Our previous findings demonstrated that ZNF224 cooperates 
with WT1 in the transcriptional modulation of apoptosis-regulating 
genes inducing pro-apoptotic gene expression in CML K562 cells. 
These results suggested a pro-apoptotic role of ZNF224 in myeloid 
leukemia. So, we decided to evaluate the expression of ZNF224 and  
WT1 mRNAs in different myeloid leukemic cell lines and in normal 
human CD34+/CD38- hematopoietic progenitors cells. The 
endogenous levels of ZNF224 and WT1 were evaluated in 
exponentially growing cells by quantitative real time PCR (Fig 11). In 
accord with a large amount of clinical and preclinical data, indicating 
an oncogenic role for WT1 in leukemogenesis [3], we observed that 
WT1 is highly expressed in all myeloid cell lines analyzed with 
respect  to CD34+ cells (Fig.11A). At the contrary, low expression 
levels of ZNF224 mRNA were detected in most of the cells analyzed: 
acute myeloid leukemia cells (AML)  JK1, PL21, NB4 (AML M3), 
PLB985 (AML M4), MV4-11 (AML M5), HEL, F36-P (AML M6) 
and chronic myeloid leukemia (CML) MEG-01 (CML), K562 (CML) 
(fig.11B). 
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Figure 11: ZNF224  and WT1 expression in mieloyd leukemia cell 
lines. Expression of ZNF224 and WT1 mRNAs in different human 
myeloid leukemic cell, lines and in normal human CD34+/CD38- 
hematopoietic progenitors cells used as control. Endogenous levels 
of ZNF224 and WT1 were evaluated by quantitative real time PCR. 
The internal control was GAPDH. Error bars represent standard 
deviations of two independent experiments. 
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3.5 Ara-C induces ZNF224 expression in K562 cells and human 
hematopoietic progenitors cells 
        To clarify the role of ZNF224 in apoptosis, we decided to 
investigate  if  ZNF224 itself could be modulated by chemotherapeutic 
agents. We chose cytosine arabinoside (ara-C) because it is one of the 
key drugs for treatment of leukemia. 
The above-reported experiment indicates that K562 cells express 
endogenous ZNF224 at low level, so we decided to expose these cells 
to increasing concentrations of ara-C (0.25µM, 0.50µM, 1µM) for 24, 
48 and 72h after which cell viability and ZNF224 mRNA levels were 
measured (Fig.12). Exposure of K562 to ara-C induced a time-
dependent cell death (Fig.12A, B and C). Then, we evaluated ZNF224 
mRNA levels by quantitative real-time-PCR (Fig.12D, E, F). In 
accordance with our previous findings that ZNF224 induced pro-
apoptotic genes expression, we observed that levels of this factor also 
increased in a time and dose dependent fashion and, apparently, an 
inverse relationship subsisted between cell viability and ZNF224 
levels.  
Surprisingly, a dose dependent effect of ara-C on cell viability was not 
observed, even if a dose dependent increase of ZNF224 was 
measured. Measurement of cell death by DAPI incorporation and 
annexin V binding confirmed lack of a dose dependent effect of ara-C 
on K562 death (Fig.13). 
To confirm that leukemic cells died by apoptosis, K562 cells were 
cultured with or without 1µM ara-C for 72h after which we evaluated 
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sub-G1 DNA content and annexin V binding by FACS analysis and 
the caspase 3  by western blot. We found that time-dependent increase 
in ZNF224 mRNA expression was accompanied by time-dependent 
induction of apoptosis and caspase-3 activation (Fig.14A, B, C), thus 
suggesting that caspase-3 activation was a direct consequence of 
ZNF224 induction. 
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Figure 12: Dose-response and time-course of ara-C induced 
ZNF224 expression. K562 cells were treated with 0.25 µM, 
0.50 µM, 1µM ara-C for 24, 48 and 72h. NT: untreated K562 
cells collected at the indicated times. (A, B, C) Viability as 
determined by trypan blue exclusion. The cell viability was 
calculated as a percentage from the viability of the untreated 
cells (NT). The results are means +/- SD from two impendent 
experiments. (D, E, F) RT-qPCR analysis of ZNF224 mRNA 
expression in K562 cells treated with 0.25µM, 0.50 µM, 1µM 
ara-C for the indicated times. Error bars represent standard 
deviations of two independent experiments.  
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Figure 13: K562 apoptosis induction by different doses of ara-C. 
K562 cells were treated with 0.25 µM, 0.50 µM and 1µM ara-C for 
72h.  NT: untreated K562 cells collected at 72h used as control. (A) 
Cell death as determined by 4’,6-diamidino-2-phenylindole (DAPI) 
positivity. (B) Apoptosis as determined by annexin V-APC 
positivity. Error bars represent standard deviations of three 
independent experiments. *P<0.05 versus untreated (NT). 
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Figure 14: Time-course of ara-C induced apoptosis.  K562 cells 
were treated with 1µM ara-C and analysed after 24, 48 and 72 h. (A) 
Apoptosis as determined by annexin V-APC staining followed by 
flow cytometry. Error bars represent standard deviations of three 
independent experiments. *P<0.05 versus untreated (NT) cells. (B) 
Cell apoptosis was measured by staining with propidium iodide and 
flow cytometric analysis. Error bars represent standard deviations of 
three independent experiments. *P<0.05 versus untreated (NT) cells. 
(C) Western blot analysis of cleaved caspase-3. One representative 
result out of three performed is presented. Molecular weight to the 
left.  
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ZNF224 induction by ara-C was confermed in human CD34+ 
hematopoietic progenitors cells. We exposed these cells to increasing 
concentrations of ara-C (0.05µM, 0.1µM, 0.25µM, 0.50µM, 1µM) for 
24 and 48h and then cell viability and ZNF224 mRNA levels were 
measured (Fig.15). We observed that the exposure to ara-C induced a 
time and dose-dependent cell death (fig.15A). Then, we evaluated 
ZNF224 mRNA levels by quantitative real-time PCR (fig.15B). 
Interestingly, we observed ZNF224 induction also at low  
concentrations of drug (0.05µM); this is in accordance with the higher 
sensitivity to the drug of CD34+ cells compared to K562.  
Next, by western blot analysis we confirmed  the induction of ZNF224 
in K562 and CD34+ cells treated with 1µM ara-C at protein level 
(fig.16A, B ). 
Finally, we confirmed that the increase of ZNF224 in ara-C-treated 
K562 cells is accompanied by an increase of proapoptotic VDR, Bax 
and Bak, and decrease of anti-apoptotic bag3 and A1/Bfl-1, as 
measured by quantitative real-time-PCR and western blot analysis 
(fig.17A, B).  
In addition, ara-C was ineffective in inducing pro-apoptotic gene 
expression in pools of K562 cells silenced for ZNF224 (Fig.17C), 
notwithstanding the decrease in WT1 mRNA expression (Fig.17A, B), 
thus confirming the role of ZNF224 as important mediator of the ara-
C-induced activation of pro-apoptotic genes. 
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Figure 15. Dose-response and time-course of ara-C induced ZNF224 
expression in human CD34+ hematopoietic progenitors cells. CD34+ 
cells were treated with 0.05µM, 0.1µM, 0.25µM, 0.50µM, 1µM ara-C for 
24 and 48 h. NT: untreated CD34+ cells collected at the indicated times. 
(A) Viability as determined by trypan blue exclusion. The cell viability 
was calculated as a percentage from the viability of the untreated cells 
(NT). The results are means +/- SD from two impendent experiments. (B) 
RT-qPCR analysis of ZNF224 mRNA expression in CD34+ cells treated 
with 0.05µM, 0.1µM, 0.25µM, 0.50µM, 1µM ara-C for the indicated 
times. Error bars represent standard deviations of two independent 
experiments.  
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Figure 16. Ara-C induces ZNF224 expression in CD34+ cells and 
K562 cells. (A) Western blot analysis of ZNF224 in CD34+ cells  and 
(B) K562 cells  treated with 1µM ara-C for 48h. One representative 
result out of two performed is presented. Molecular weight to the left. 
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Figure 17: Modulation of apoptosis regulating genes by ara-C. 
(A) RT-qPCR analysis of mRNA levels in K562 cells treated with 
1µM ara-C for 72hr.  NT: untreated K562 cells collected at 72h 
used as control. mRNA level of matrin3, used as negative control, 
was measured to demonstrate the specificity of ara-C effect on 
apoptosis regulating genes. Error bars represent standard 
deviations of three independent experiments. *P<0.05 versus 
control;   **P=0.006 versus control; ns, not significant. (B) Total 
protein extracts were analyzed by western blot with the indicated 
antibodies. G3PDH was used to monitor equal loading conditions. 
One representative result out of three performed is presented. 
Molecular weight to the left.  
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Figure 17: Modulation of apoptosis regulating genes by ara-C.  
(C) RT-qPCR analysis of mRNA levels of pools of K562 cells 
silenced for ZNF224 and treated with 1µM ara-C for 72h (ZNF224 
shRNA+ara-C 1µM) or of pools of K562 cells stably transfected with 
scrambled shRNA treated with 1µM ara-C for 72h (scrambled 
shRNA+ara-C 1µM) used as negative control. Error bars represent 
standard deviations of three independent experiments. *P<0.05 versus 
scrambled shRNA treated with ara-C. 
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3.6 ZNF224 overexpression enhances the apoptotic effect mediated 
by ara-C in K562 cells  
        To confirm our previous findings that there is  a strong 
correlation between ZNF224 induction by ara-C and pro-apoptotic 
gene expression,  we evaluated the apoptotic response to ara-C in 
pools of K562 cells stably overexpressing ZNF224 (ZNF224-FLAG) 
or ZNF224-silenced (ZNF224 silencing) or overexpressing WT1(-
KTS). 
These pools of clones and their corresponding controls were cultured 
with or without 1µM ara-C for 72h and then viability and apoptosis 
were analyzed. 
As shown in figures 18A and 18D, K562 cells expressing ZNF224-
FLAG were significantly more sensitive to the effects of ara-C on cell 
viability and apoptosis with respect to K562 cells not expressing 
ZNF224-FLAG. According to these findings, silencing of ZNF224 
increased cell viability and reduced the number of annexin V-positive 
cells after exposure to ara-C (Fig.18B and E). These results support a 
role for ZNF224 in the apoptotic response to ara-C.  
Moreover, we observed that WT1(-KTS) overexpressing K562 cells 
are protected, at least partly, from cell death further confirming the 
antiapoptotic  role of  WT1 (Fig.18C and F).  
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Figure 18: ZNF224 enhances ara-C induced apoptosis.  
A, D: The cell viability and the apoptosis of K562 cells expressing or 
not expressing ZNF224-FLAG, measured after treatment with 1µM 
ara-C for 72h. B, E: The cell viability and the apoptosis of pools of 
K562 cells stably transfected with ZNF224 shRNA or scrambled 
shRNA, measured after treatment with 1µM ara-C for 72h. C, F: The 
cell viability and the apoptosis of pools of K562 cells retrovirally 
transduced with WT1(-KTS) or control empty vector (pMIG), 
measured after treatment with 1µM ara-C for 72h. NT: untreated 
cells collected at 72h. The cell viability was determined by trypan 
blue exclusion. The cell viability was calculated as a percentage 
from the viability of the untreated cells (NT) set as 100%. Apoptosis 
was determined by annexin V-APC positivity followed by flow 
cytometry.  Error bars represent standard deviations of three 
independent experiments. *P<0.05, **P<0.005 versus untreated 
(NT) cells. 
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4.DISCUSSION  
         
        Regulation of apoptosis is a critical function of WT1 and is due 
at least in part to the modulation of expression of bcl-2 family 
members [33]. WT1 is highly expressed in leukemia cells and its 
overexpression is associated with a poor response to therapy [55]. We 
recently showed that WT1 positively regulates the expression of the 
antiapoptotic gene bag3, by a transcriptional mechanism. WT1-
mediated increase in BAG3 protein levels contributes to the pro-
survival role of WT1 in leukemic cells [38]. The effects of WT1 on 
target gene expression appear to be isoform-specific, strongly 
influenced by different cellular contexts and by physical interactions 
with other proteins that are known to modulate WT1 transcriptional 
function [39-43]. We previously identified the Krüppel-like zinc 
finger protein, ZNF224, as a novel WT1-interacting factor involved in 
WT1 transcriptional regulation of VDR promoter [44]. In this study, 
we provide further evidence of ZNF224 acting as a transcriptional co-
regulator of WT1 and playing a relevant role in the control of WT1-
mediated expression of apoptosis-regulating gene in the CML cell line 
K562, thus pointing to a role for the ZNF224/WT1 interaction in 
leukaemia. Indeed, chromatin immunoprecipitation assays revealed 
that ZNF224 binds to the promoter of WT1 target genes only if 
recruited by WT1 itself, thus indicating that ZNF224 acts as a 
transcriptional co-factor of WT1, without directly binding to promoter 
DNA sequences. A combination of over-expression and knockdown 
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analyses of both ZNF224 and WT1 in K562 cell line revealed that 
ZNF224 exerts a dual effect on the expression of WT1 target genes, 
acting as a co-activator of WT1 in the regulation of pro-apoptotic 
genes and suppressing WT1-mediated trans-activation of anti-
apoptotic genes.  
These data demonstrate that ZNF224, beyond its known role of DNA 
binding transcriptional repressor [49], may act in a DNA binding-
independent mode of transcriptional regulation, through its ability to 
interact with another trascription factor, i.e. WT1. Our finding thus 
reveals a still undiscovered function for ZNF224 as transcriptional co-
regulator.  
However, we cannot rule out that ZNF224 could participate in the 
regulation of apoptosis also through the direct binding to promoters of 
not yet identified target genes, where it acts as a repressor.  
Other Krüppel-like zinc finger proteins are involved in cell 
proliferation, apoptosis and neoplastic transformation [56]. For 
instance, ZBP-89 has been show to be an important regulator in 
apoptosis and cell growth and can induce apoptosis through 
mechanisms both dependent and independent of p53 [57]; ZNF23 
inhibits cell cycle progression via up-regulation of p27kip-1 [58]; 
APAK (ATM ad p53 associated KZNF protein) specifically inhibits 
p53-mediated apoptosis [59]; ZNF382 exerts a pro-apoptotic role by 
repressing NF-KB and AP1 signaling and by inhibiting the expression 
of multiple oncogenes, including the NF-kB upstream factors STAT3, 
STAT5B, ID1 and IKBKE  [60].  
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Although KRAB-containing zinc-finger proteins are thought to 
function mainly as transcriptional repressors, it has been recently 
reported that ZBRK1 and ZNF263 display activating as well as 
repressing effects on target gene transcription, by yet unknown 
mechanisms and co-regulators [61,62]. Indeed, several lines of 
evidence indicate that specific transcription factors can use distinct 
combinations of co-regulator complexes and enzymatic activities 
required for modifying chromatin machinery, in a cell-, gene-, and 
promoter-specific manner. 
Deciphering the role of ZNF224 as a transcriptional regulator of WT1, 
identifying additional components of the WT1/ZNF224 complex and 
elucidating how alterations of the WT1/ZNF224 complex affect the 
expression of apoptosis-regulating genes will shed further light into 
the molecular mechanisms of apoptosis regulation.  
Furthemore, in this study we observed that (CML) K562 cells express 
low level of ZNF224, and that cytosine arabinoside (ara-C) induced 
ZNF224 expression in K562 cells; ara-C is the key agent for the 
treatment of acute myeloid leukemia [63]. After being transported into 
leukemic cells, ara-C is phosphorylated  by several enzymes including 
deoxycytidine kinase (dCK) to ara-C triphosphate (ara-CTP), an active 
metabolite, and then incorporated into DNA, thereby inhibiting DNA 
synthesis. Ara-C induced DNA damage triggers a wide spectrum of 
intracellular signaling elements that may contribute to cytotoxicity 
[64,65]. However, the molecular mechanism coupling ara-C-induced 
DNA damage to the initiation of cell death have not been yet well 
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disclosed.  
We demonstrated that exposure of K562 cells and human 
hematopoietic progenitors cells CD34+/CD38- to ara-C increased 
ZNF224 transcript in a time- and dose-dependent manner, suggesting 
an important role for the anti-leukemic drug in regulating expression 
of this protein.  
ZNF224 induction is associated with an increase in apoptotic cell 
death, that correlates with downregulation of antiapoptotic WT1 target 
genes such as bag3 and A1/Bfl1 and upregulation of proapoptotic 
molecules such as VDR, Bax and Bak.    
On the other hand, lack of correlation between cell death values and 
ara-C doses may be due to a concomitant activation mechanisms, 
responsible for apoptosis resistance, that hamper the expected cell 
death increase. Such an hypothesis is in accordance with the notion 
that K562 are resistant to ara-C induced cell death [66,67].   
Finally, notwithstanding the heterogeneity of pool of clones, the 
increased sensitivity to ara-C induced apoptosis in pools of clones 
overexpressing ZNF224, is a further element in support of the pro-
apoptotic role of this zinc finger protein. WT1(-KTS) overexpression 
was able to counteract, at least in part, the proapoptotic effect of 
ZNF224 following ara-C stimulation, thus confirming the relevant 
role of ZNF224/WT1 interaction in fine tuning of apoptotic-gene 
expression.  
Taken together, our findings establish a relevant role for ZNF224 in 
apoptotic processes in CML thus indicating  that ZNF224 could 
Discussion 
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provide a critical link between ara-C induced DNA-damage and  the  
expression  of  pro-apoptotic genes in leukemia cells.  
A better definition of the molecular mechanism coupling ara-C-
induced DNA damage to the initiation of cell death could lead to the 
development of new cancer chemotherapy strategies used for the 
treatment of myeloid leukemia.  
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LETTER TO THE EDITOR
WT1 protein is a transcriptional activator of the antiapoptotic bag3 gene
Leukemia advance online publication, 22 April 2010; doi:10.1038/
leu.2010.68
WT1 gene, originally identified as a tumor suppressor involved
in the formation of Wilms’ tumor of the kidney, was
subsequently described to have an oncogenic role in a variety
of tumors from different origins, including leukemias.1 In
comparison to normal progenitor cells, it is overexpressed in
acute lymphoblastic and myeloblastic leukemia, and in the
blast crisis phase of chronic myelogenous leukemia;1,2 high
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Figure 1 WT1 positively regulates bag3 expression through a transcriptional mechanism. (a) Chromatin immunoprecipitation (ChIP) was
performed in K562 cells with anti-WT1 antibody (C19; Santa Cruz Biotechnology, Santa Cruz, CA, USA), as described,8 or with nonspecific IgGs
as control. The resultant samples were analyzed by standard PCR using specific bag3 primers (forward: 50-tcggcgcaaaggagaggga-30; reverse:
50-ggccagttgctacctccct-30). As a negative control, PCR was performed using GAPDH-specific primers (forward: 50-aggtcatccatgacaactttgg-30;
reverse: 50-ttgtcataccaggaaatgagct-30). Schematic representation of the bag3 promoter region that contains the WT1 DNA-binding sites is reported
in the lower part of the panel. (b) HEK293 cells were transiently transfected using Lipofectamine Reagent (Invitrogen, Carlsbad, CA, USA) in
six-well plates with 0.2 mg of a luciferase reporter plasmid containing bag3 promoter and 0.25, 0.5 or 0.7 mg of WT1(KTS) or WT1(þKTS)
expression plasmid. The Dual-Luciferase Reporter Assay (Promega Corporation, Madison, WI, USA) was performed 24h after the transfection. Bar
graphs depict the means of fold increase of transcription activities with respect to bag3 promoter activity (triplicate determinations). WT1(KTS)
and WT1(þKTS) protein overexpression was evaluated by western blot analysis and GAPDH was used as loading control. (c) HEK293 cells were
transiently transfected using Lipofectamine Reagent (Invitrogen) in six-well plates with 0.5, 1 or 2 mg of a WT1(KTS) or WT1(þKTS) expression
plasmid. At 48 h after transfection, total RNA was isolated using TRIzoL reagent (Invitrogen) and cDNA was synthesized from 1mg of each RNA
using MMLV reverse transcriptase (Invitrogen). RNA levels were measured by real-time PCR in a Bio-Rad iCycler using Master Mix (Bio-Rad,
Berkeley, CA, USA) and specific primers for bag3 or b-actin (forward: 50-cgacaggatgcagaaggaga-30; reverse: 50-cgtcatactcctgcttgcttgctg-30),
respectively. Standard deviations were calculated from triplicate measurements. (d) HEK293 cells were treated as described in (c); total protein
lysates were obtained and resolved by 10% SDS–PAGE gels and were immunoblotted. Extracts were analyzed for their content of BAG3 protein in
western blotting using a polyclonal anti-BAG3 antibody (TOS-2; Enzo Biochem, New York, NY, USA). An antibody recognizing b-actin was used
to monitor equal loading conditions. (e) K562 cells were transiently transfected using Lipofectamine 2000 Reagent (Invitrogen) with 2 mg of a short
interfering RNA plasmid (RNAi) to silence WT1, or 2 mg of a scrambled RNA; after 48 h cell RNA and total protein extracts were prepared. RNA
levels were measured by real-time PCR in a Bio-Rad iCycler using Master Mix (Bio-Rad) and primers specific for WT1, bag3 or b-actin. Proteins
were analyzed by western blot analysis using anti-WT1 and anti-BAG3 (TOS-2) antibodies. Anti b-actin antibody was used as control.
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levels of the protein are associated with a poor response
to therapy.1,3 WT1 knockdown by antisense oligonucleotides or
RNA interference was shown to induce apoptosis; conversely,
its overexpression in myeloid leukemia cells protected against
cell death. Modulation of some members of the bcl-2 family has
been associated with apoptosis inhibition by WT1.1,3
Among proteins that regulate apoptosis in leukemia cells,
a role is assigned to BAG3, a member of the family of proteins
that, through their BAG domain, interact with HSC70/HSP70
heat shock proteins. bag3 gene expression is constitutive in
some tumor types, including leukemias; in these cells, BAG3
protein has been shown to sustain cell survival and down-
modulate cell apoptotic response to drugs, by either HSP70-
dependent or -independent mechanisms.4–7
Here we report that WT1 induces bag3 gene expression. This
finding identifies a novel target of WT1 protein involved in
apoptosis regulation in leukemia cells.
As using in silico analysis we had found two putative WT1
binding sites on the bag3 promoter, we decided to investigate
whether WT1 is directly recruited onto the bag3 promoter using
a chromatin immunoprecipitation assay (ChIP) in K562 cells,
which express significant amounts of endogenous WT1 and
BAG3. Chromatin was immunoprecipitated with anti-WT1 anti-
bodies. Subsequent PCR analysis, performed using oligonucleo-
tides covering the putative WT1 binding sites, revealed that
WT1 bound to the bag promoter sequences (350-bp band),
whereas rabbit IgG antibody controls did not (Figure 1a). WT1
protein has two major isoforms, designated WT1(-KTS) and
WT1(+KTS), containing an extra three aminoacids (KTS)
between the third and fourth zinc fingers; WT1(KTS) appears
to exert its effect mainly as a transcriptional factor, whereas
WT1(þKTS) is involved in RNA processing.1 To investigate the
transcriptional modulation of bag3 promoter by WT1, we
introduced a luciferase reporter plasmid containing the bag3
promoter into HEK293 cells and analyzed luciferase levels in the
presence of increasing amounts of WT1(KTS) or WT1(þKTS)
expression plasmids. As shown in Figure 1b, the ‘transcriptional
isoform’, WT1(KTS), enhanced bag3 promoter activity in a
dose-dependent manner, whereas transfection of the ‘post-
transcriptional isoform’, WT1(þKTS), did not influence the
transcriptional activity.
To assess whether forced expression of WT1 isoforms could
modulate endogenous bag3, we transfected HEK293 cells with
increasing concentrations of the expression vectors encoding
WT1(KTS) or WT1(þKTS) and evaluated bag3 mRNA and
BAG3 protein levels by quantitative real-time-PCR and western
blot analyses, respectively. We observed a progressive increase
in the levels of bag3 RNA and BAG3 protein in cells transfected
with increasing amount of WT1(KTS), and not in those
transfected with WT1(þKTS) (Figures 1c–d), confirming the
transcriptional activation of endogenous bag3 gene by WT1.
To provide a further argument for bag3 regulation by WT1,
we evaluated bag3 expression in K562 cells following
small interfering RNA (RNAi)-mediated knockdown of WT1.
As shown in Figure 1e, the levels of bag3 mRNA in WT1 knock-
down cells were decreased by about 40%; western blotting
confirmed downmodulation of BAG3 protein.
Altogether, these observations ascribe a role to WT1 in bag3
gene regulation.
We next evaluated the effect of WT1 silencing on apoptosis.
In K562 cells treated with the proapoptotic agent phenethyl
isothiocyanate (PEITC), WT1 silencing significantly enhanced
apoptosis, as assessed by flow cytometry, with respect to control
scrambled RNA (Figure 2a). Conversely, BAG3 protein appeared
to exert an antiapoptotic effect against PEITC treatment,
since its overexpression obtained by cell transduction with a
bag3 cDNA-carrying adenovirus (AdhBAG3) downmodulated
PEITC-induced apoptosis (Figure 2b). We therefore investigated
whether the enhancement of apoptosis induced by WT1 knock-
down was reversed by bag3 overexpression. Indeed, in cells
infected by AdhBAG3, cell survival was rescued by more
than 25% compared to cells treated with WT1 RNAi alone
(Figure 2a). Therefore, WT1 inhibition of apoptosis appeared
to be in part mediated by BAG3 protein.
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Figure 2 WT1 knockdown affects bag3 (gene) expression and enhances apoptosis. (a) K562 cells were transiently transfected using Lipofectamine
2000 Reagent (Invitrogen) with a plasmid expressing WT1 RNAi or a scrambled sequence. After 48 h, cells were exposed to PEITC (10mM) for 18 h
and percentage of apoptotic nuclei was measured by cell permeabilization and staining with propidium iodide, in flow cytometry, as described.6
(b) Adenoviral constructs were generated using the BD Adeno-X Expression Systems 2 (BD Biosciences-Clontech, Palo Alto, CA, USA). For
AdhBAG3 construction, bag3 full-length cDNA from human brain was cloned in pDNR-CMV vector and the gene expression cassette was
transferred to the Adenoviral Acceptor Vector pLP-Adeno-X-PRLS viral DNA, containing DE1/DE3 Ad5 genome, by Cre-loxP-mediated
recombination. AdNull, devoid of bag3 cDNA, was used as a control. K562 were transduced with AdhBAG3 or with control AdNull using a
multiplicity of infection of 100 (100 MOI); after 48 h cells were exposed to PEITC at the indicated concentrations for 18 h, then apoptosis was
measured by flow cytometry. Graph depicts the percentages of apoptotic nuclei. Significance between two groups was calculated by Student’s
t-test. For western blot analysis, whole-cell lysates were obtained and analyzed for BAG3 content. GAPDH was assessed to verify equal loading
conditions. (c) K562 were transfected with WT1 RNAi or a scrambled sequence; after 24 h cells were transduced with AdhBAG3 or AdNull
and, after additional 24 h, exposed to PEITC (10 mM) for 18 h. The graph depicts the percentage increase in cell survival with respect to WT1
RNAi-treated cells.
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The above-reported findings show that WT1 protein regulates
bag3 expression and thatWT1-mediated increase in BAG3 protein
levels contributes to the prosurvival role of WT1 in leukemic cells.
The identification of bag3 as a target gene of WT1 improves our
understanding of apoptosis regulation by this factor. We believe
that the associated impacts of BAG3 and WT1 in leukemia cell
survival and response to therapy deserve further investigation.
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Wilms’ tumour suppressor gene, WT1, is mutated/deleted in ∼15% of Wilms’ tumours, highly expressed in
the majority of other cancers and is essential for normal embryonic development. The gene encodes multiple
isoforms of a zinc-finger (ZF) protein with diverse cellular functions, in particular participating in both tran-
scriptional and post-transcriptional gene regulation. Physical interactions of other cellular proteins with WT1
are known to modulate its function. However, despite the isolation of several WT1-binding proteins, the
mechanisms involved in regulating WT1 activities are not clearly understood. In this study, we report the
identification of the Kru¨ppel-like ZF protein, ZNF224, as a novel human WT1-associating protein and demon-
strate that ZNF224 and its isoform ZNF255 show a specific pattern of interaction with the WT1 splicing var-
iants WT1(2KTS) and WT1(1KTS). These interactions occur in different subcellular compartments and are
devoted to control different cellular pathways. The nuclear interaction between ZNF224 and WT1(2KTS)
results in an increase in trascriptional activation mediated by WT1, implying that ZNF224 acts as a
co-regulator of WT1, whereas, on the contrary, the results obtained for ZNF255 suggest a role for this protein
in RNA processing together with WT1. Moreover, our data give the first functional information about the
involvement of ZNF255 in a specific molecular pathway, RNA maturation and processing.
INTRODUCTION
The KRAB (Kru¨ppel-associated box) domain-containing zinc-
finger (ZF) genes are part of the poly-ZF family that constitu-
tes the largest mammalian transcriptional regulatory gene
family. Almost 50% of transcription factor genes in the
human genome encode ZFs, of which 40% contains
KRAB domains (1). Typically, KRAB-ZF proteins mediate
transcriptional repression yet, to date, little else is known of
their function as many KRAB-ZF genes are human-specific,
so loss-of-function approaches using gene targeting in mouse
embryonic stem cells are not possible. Recently, we have
shown that the ZNF224 protein functions as a transcriptional
repressor of the human aldolase A gene, consistent with the
presumed function of the KRAB-ZF family (2,3). Further-
more, we have demonstrated the existence of an alternatively
spliced isoform arising from the ZNF224 gene, known as
ZNF255 or bone marrow zinc finger 2. These two isoforms
have distinct pattern of distribution within the cell, implying
that they perform different cellular functions. Unlike
ZNF224 that shows a homogenous nuclear distribution,
ZNF255 is distributed throughout the cell and is present also
in nucleoli and cytosol. This splicing isoform displays little
affinity for the DNA consensus sequence bound by ZNF224
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(4). A transcriptional repression role for ZNF255 has pre-
viously been suggested, due to the presence of a Kru¨ppel-
related novel transcriptional repressor module, nominated as
KRNB: ZNF255 has been shown to interact with Wilms’
tumour 1 (WT1) protein and inhibit WT1-mediated transcrip-
tional activation (5). Although the study of KRAB-ZF genes is
in its infancy, ZNF224 and ZNF255 display typical features of
this group of ZF proteins that originate from a single gene by
alternative splicing or different promoter usage, giving rise to
multiple isoforms with distinct subcellular localizations and
strong functional differences (6,7).
In contrast to the KRAB-ZF family, the WT1 ZF protein,
WT1, has been conserved throughout vertebrate radiation
and has been extensively studied. Initially identified as a
tumour suppressor gene, whose mutations and deletions are
associated with urogenital disease and the development of
Wilms’ tumour (8), WT1 has been shown to be essential not
only for the development of the urogenital system, but also
for numerous other tissues/organs, including the heart (9,10).
The WT1 gene encodes at least 24 different isoforms
through a combination of alternative splicing or translation
initiation sites (11,12). Many of the isoforms are found only
in mammals and have yet to be associated with a specific func-
tion (13,14). However, the variable splicing of exon 9, leading
to the insertion or exclusion of the amino acids lysine, threo-
nine and serine (KTS) between the third and fourth ZFs gives
rise to the WT1 isoforms more extensively studied,
WT1(+KTS) and WT1(2KTS). This splicing site is con-
served in all vertebrates and is essential for normal develop-
ment (15). Moreover, the correct ratio of (+KTS)/(2KTS)
isoforms must be strictly maintained as heterozygous
mutations affecting this alternative splicing event have been
shown to be the cause of the Frasier syndrome, a urogenital
disorder characterized by glomerulosclerosis and gonad dys-
genesis (16). Although showing redundancy in vivo, these
two major WT1 isoforms have distinct properties at the mol-
ecular level. The (2KTS) isoform acts mainly as a transcrip-
tional factor, binding GC-rich DNA sequences with a high
affinity (17,18). It can work as an activator, co-activator or
repressor depending on cellular context and cofactor inter-
actions (19). As a transcriptional factor, WT1 is able to modu-
late the expression of a wide number of genes involved in
tissue differentiation, as podocalyxin and VDR (20,21), in
apoptosis, e.g. bcl-2 (22), bax and bak (23), or in cell cycle
control, as Cyclin E (24). Moreover, the transcriptional regu-
latory properties of WT1 are thought to be influenced by an
interaction with an increasing number of interacting partners,
such as par-4 or BASP1 (19,25,26). WT1 can also act as a
transcription cofactor for other DNA-binding proteins
(27,28). In contrast, there is evidence that the WT1(+KTS)
isoform displays little affinity for DNA (29–31), instead
showing affinity for RNA and has been implicated in transcript
processing. The WT1(+KTS) isoform is present in nuclear
domains rich in splicing factors and has been found associated
with snRNPs (17,32,33) and two proteins involved in splicing,
U2AF65 and WTAP (34,35). Recently, it has been found that
WT1 binds the mRNA of alpha-actinin 1 (36), is also a com-
ponent of mRNP complexes (37) and is associated with trans-
lating polysomes (38). This observation establishes a link
between WT1 and the regulation of translation and extends
its potential range of functions in the cell. The recent finding
that WT1 shuttles between the nucleus and cytoplasm (38)
places WT1 at every stage of gene expression from initiating
transcription through mRNA splicing and translocation to
translation. The concept of transcription factors shuttling
between nucleus and cytoplasm and acquiring new functions
has been proposed and is likely to occur via additional inter-
acting protein partners (39).
In the present study, we characterized physical and func-
tional interactions of ZNF224 and its isoform ZNF255 with
WT1 splice variants (+KTS) and (2KTS). Our results show
a specific interaction of ZNF224 with the (2KTS) isoform
and suggest that ZNF224 may act as a transcriptional
co-regulator of WT1(2KTS) (as shown by co-transfection
experiments using a known WT1 target gene, VDR). On the
contrary, ZNF255 interacts and co-localizes with both WT1
isoforms, with a preference for the (+KTS) isoform, suggesting
a role for this interaction in RNA maturation and post-
transcriptional control. As well as extending our understanding
of the molecular interactions of WT1 isoforms in different sub-
cellular compartments, our results allow us to suggest, for the
first time, a cellular role for ZNF255 and provide a striking
example of how recently evolved ZF proteins, such as
ZNF255 and ZNF224, can function to modulate the activity
of an ancient, evolutionary conserved ZF protein, WT1.
RESULTS
WT1 interacts in vivo with ZNF224 and ZNF255
The protein ZNF255 was previously identified as an interact-
ing partner of WT1 by affinity chromatography and shown
to inhibit WT1 transactivation (5). We recently demonstrated
that ZNF255 is in fact an alternatively spliced variant of the
transcriptional repressor ZNF224 that lacks the KRAB
domain while retaining 19 ZFs. Furthermore, ZNF255 displays
a markedly reduced transcriptional repressor activity and
decreased affinity for the AldA-NRE motif, when compared
with the effects of its KRAB-containing isoform ZNF224 (4).
In order to investigate whether WT1 also binds to the ZNF224
protein, we performed co-immunoprecipitation assays of the
endogenous proteins in the leukaemia cell line K562, which
express high levels of WT1. Total protein extracts were
immunoprecipitated with an anti-WT1antibody (F6) directed at
the N-terminus and the subsequent western blot probed with an
antibody that recognizes ZNF224 and ZNF255 isoforms (T3),
revealing that both proteins are able to interact with WT1
(Fig. 1A). As a negative control, neither ZNF224 nor ZNF255
is immunoprecipitated with rabbit IgG.
The proteins ZNF224 and ZNF255 show different subcellu-
lar localization patterns: ZNF224 is predominantly a nuclear
protein, whereas ZNF255 is present in the nucleus and in
the cytoplasm. WT1 localization both in the nucleus and in
the cytoplasm has been interpreted as reflecting distinct func-
tional roles in the different subcellular compartments (37).
These findings led us to investigate whether the interaction
between the ZNF224/ZNF255 isoforms and WT1 occurred
in specific compartments. To look at this, we conducted an
immunoprecipitation assay for endogenous proteins on
nuclear and cytoplasmic extracts of K562 cells. Western blot
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analysis of immunoprecipitated proteins performed with T3
antibody shows that ZNF224 interacts with WT1 only in the
nucleus, whereas the interaction between WT1 and ZNF255
occurs both in the nucleus and in the cytoplasm (Fig. 1B).
The extract purity was controlled with anti-myc and anti-
tubulin antibodies (Fig. 1C), confirming that the cytoplasmic
extracts were free from nuclear contamination and vice
versa. These specific interactions were further validated in
HEK293 cells, where ectopic WT1 and ZNF224 or ZNF255
proteins fused to a FLAG epitope were co-expressed and sub-
sequently immunoprecipitated with the anti-WT1 antibody in
a similar manner (data not shown).
ZNF224 and ZNF255 interact with specific WT1 isoforms
Given the differential interactions of ZNF224/ZNF255 with
WT1 in particular subcellular compartments and increasing
evidence that WT1 isoforms are involved in different stages
of gene expression regulation, we decided to consider
whether the proteins ZNF224 and ZNF255 interact specifically
with the WT1(+KTS) and (2KTS) isoforms, in order to
investigate potential biological roles of these interactions.
Specific antibodies to the WT1 isoforms do not exist, so we
performed immunoprecipitation assays with the C-terminal
anti-WT1 antibody (C19) on cell lysates from HEK293 cells
co-transfected with plasmids coding for WT1(2KTS) or
WT1(+KTS) together with plasmids coding for ZNF224-
FLAG or ZNF255-FLAG, respectively. ZNF224-FLAG was
specifically co-immunoprecipitated by anti-WT1 antibodies
in the presence of the WT1(2KTS) isoform (Fig. 2A), but
not with the WT1(+KTS) isoform (Fig. 2C). On the contrary,
ZNF255 was co-immunoprecipitated with both isoforms,
WT1(2KTS) and WT1(+KTS) (Fig. 2B and D). Moreover,
this experiment is consistent with the subcellular localization
of the isoforms: the interaction between ZNF224 and
WT1(2KTS) occurs in the nucleus, whereas ZNF255 and
WT1(+/2KTS) interact in both the nucleus and the
cytoplasm.
In order to visualize these interactions and confirm the result
of the immunoprecipitation experiments, immunofluorescence
under confocal microscopy was performed on COS7 cells
transfected with the expression plasmids described above.
Figure 1. Immunoprecipitation of ZNF224 and ZNF255 with the Wilms’ tumour protein WT1. (A) The anti-WT1 F6 antibody or control immunoglobulin (IgG)
was used in immunoprecipitation assay on K562 total lysates. Western blot with the antibody against ZNF224 and ZNF255 (T3) shows that both proteins interact
with WT1. Lower panel shows western blot with anti-WT1 F6 antibody. (B) The anti-WT1 F6 antibody was used in immunoprecipitation assay on nuclear and
cytoplasmic extract of K562 cells. Western blot with the antibody T3 shows that ZNF224 interacts with WT1 only in the nucleus, whereas ZNF255 is present in
nuclear and cytoplasmic immunoprecipitates. The additional bands detected by the T3 antibody in extracts may represent additional isoforms of ZNF224/255 or
closely related, cross-reacting KRAB-ZNF proteins. (C) The purity of fractioned extract was checked by western blot with anti-c-myc and anti-tubulin.
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Transfected cells, observed under confocal microscopy, show
the expected subnuclear localization patterns of WT1(+KTS)
and (2KTS) isoforms, consistent with their proposed roles:
the ‘transcriptional isoform’, WT1(2KTS), gave rise to the
expected diffuse nuclear localization apart from nucleoli
(Fig. 3A and C), typical of a transcription factor, whereas
the ‘RNA processing isoform’, WT1(+KTS), is present in
the nuclear speckles, a pattern commonly associated with
nuclear splicing factors (Fig. 3B and D). Merging of the
double stained planes revealed the signal of ZNF224-FLAG
protein (red) overlapping strikingly with the WT1(2KTS)
signal (green) (Fig. 3A), but showing no overlap with
the WT1(+KTS) signal (Fig. 3B), in accordance with the
immunprecipitation results. Furthermore, consistent with the
immunoprecipitation, ZNF255-FLAG partially overlaps with
the WT1(2KTS) signal (Fig. 3C) and shows a nuclear
speckled pattern that strikingly overlaps with the signal of
WT1(+KTS) isoform (Fig. 3D), such that almost all
WT1(+KTS) speckles (green) are associated with ZNF255.
Note that the diffuse versus speckled localization of WT1 iso-
forms is not 100% discrete, as reported by Larsson et al. (17).
As a whole, the results from the immunoprecipitation and
immunofluorescence assays demonstrate that both ZNF224
and ZNF255 interact with WT1 in an isoform-specific
manner. Since WT1(2KTS) and WT1(+KTS) have been
suggested to control separate aspects of gene expression
regulation, it is tempting to speculate that there are distinct
functional roles for these protein complexes in the cell.
The specific nuclear interaction between ZNF224 and
WT1(2KTS) suggests that these proteins cooperate in tran-
scriptional regulation. The results obtained for ZNF255 and
WT1, on the contrary, suggest an involvement in a different
cellular process, such as RNA processing.
ZNF224 enhances WT1-mediated transcriptional
activation
It is well documented that physical interactions of WT1 with
other cellular proteins can modulate its transcriptional activity.
Therefore, as both WT1(2KTS) and ZNF224 are transcrip-
tional factors, we first hypothesized that their specific
nuclear interaction would be involved in transcriptional
regulation.
To determine the effect of the WT1(2KTS)/ZNF224 inter-
action on WT1-dependent transcriptional regulation, we
carried out transfection experiments in HeLa cells. We chose
a reporter plasmid (phVDR-LUC) containing the human
vitamin D receptor promoter, a known target of the WT1 tran-
scriptional activation, cloned upstream of the Firefly Lucifer-
ase gene (21). As shown in Figure 4A, the co-transfection of
a fixed amount of pcDNA3WT1(2KTS) and increasing con-
centrations of p3XFLAG-ZNF224 causes a dose-dependent
up-regulation of the phVDR-LUC transcriptional activity
(lanes 5–7). The specificity of the effect of ZNF224 on the
activation function of WT1 was demonstrated by
co-transfection of a construct expressing Nrf2 as a negative
control (p3XFLAG-Nrf2), which does not influence the luci-
ferase activity (lanes 11–13). Furthermore, increasing concen-
trations of p3XFLAG-ZNF224 had no effect on phVDR-LUC
in the absence of WT1 (lanes 8–10). On the contrary, as
shown in Figure 4B, co-transfection of increasing amount of
p3XFLAG-ZNF255 (lanes 5–7) with WT1(2KTS) does not
significantly affect phVDR-LUC transcriptional activity.
Given that ZNF224 only activates transcription in the pres-
ence of WT1, we performed chromatin immunoprecipitation
(ChIP) experiments to investigate the nature of this inter-
action, at the molecular level, on endogenous target genes
Figure 2. ZNF224 and ZNF255 show different affinity for the (+/2KTS) WT1 isoforms. HEK293 cells were co-transfected with p3XFLAG-ZNF224 and
pcDNA3-WT1(2KTS) (A) or with p3XFLAG-ZNF224 and pcDNA3-WT1(+KTS) (C) C19 antibody was used to immunoprecipitate the different isoforms
of WT1 from nuclear and cytoplasmic lysate. The immunoprecipitated complexes were probed with the anti-FLAG antibody. In (A), a specific interaction
of ZNF224 with WT1(2KTS) in the nucleus is shown. No interaction was observed between ZNF224 and WT1(+KTS) (C). The same experiment was per-
formed on HEK293 transfected with p3XFLAG-ZNF255 and pcDNA3-WT1(2KTS) (B) or pcDNA3-WT1(+KTS) (D). Western blot shows that ZNF255 inter-
acts with both WT1 isoforms in nuclear and cytoplasmic compartments.
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of both WT1 (VDR) and ZNF224 (AldA). Chromatin was
prepared from HEK293 cells transfected with pcDNA3WT1
(2KTS), or p3XFLAG-ZNF224, or co-transfected with
pcDNA3WT1(2KTS) and p3XFLAG-ZNF224, respectively.
Chromatin was immunoprecipitated with anti-WT1 (Fig. 4C,
left panel) or anti-FLAG (Fig. 4C middle and right panels)
antibodies. Real-time PCR analyses were performed using
oligonucleotides flanking the WT1-binding sites on the
VDR promoter or the AldA-NRE element, which we had pre-
viously characterized as a ZNF224-binding site (2). As
expected, WT1 was bound to VDR promoter region and
not to AldA-NRE element (Fig. 4C, left panel), whereas
ZNF224 was bound to AldA-NRE element and not to VDR
promoter region (Fig. 4C, middle panel), thus confirming
that ZNF224 alone has no effect on VDR. When ZNF224
was over-expressed along with WT1, it was found to bind
the VDR promoter, thus demonstrating that recruitment of
ZNF224 to VDR promoter requires WT1 (Fig. 4C, right
panel). These results provide experimental evidence that
WT1 and ZNF224 interact at the chromatin level in a
kidney cell line.
In order to determine the consequences of this interaction in
a more physiologically relevant setting, we carried out
siRNA-mediated knockdown of ZNF224 in K562 cells and
measured the expression of endogenous VDR and of aldolase
A mRNA, taken as a control. Figure 5 shows that knockdown
of ZNF224 leads to a considerable increase in aldolase A
mRNA expression, according to the ZNF224 repression role
on aldolase A gene transcription (40); at the same time,
ZNF224 silencing leads to an appreciable reduction in VDR
expression both at mRNA (Fig. 5A) and protein levels
(Fig. 5B), demonstrating that not only can exogenous
ZNF224 augment WT1-mediated VDR expression but also
ZNF224 contributes to the normal physiological expression
of the VDR gene.
These experiments demonstrate that the protein ZNF224
can cooperate with WT1 in the transcriptional regulation of
the VDR promoter, enhancing the gene activation mediated
by WT1, and that this cooperation does not involve direct
DNA binding of ZNF224. On the other hand, the poor tran-
scriptional effect of p3XFLAG-ZNF255 supports the notion
that the isoform ZNF255 is mainly involved in a different
process, such as RNA processing.
Conversely, employing similar transient transfection exper-
iments, we did not observe functional consequences of the
WT1(2KTS)/ZNF224 interaction on the transcriptional
regulation of the only known ZNF224 target sequence
(AldA-NRE), suggesting that WT1 does not play a role in
ZNF224-dependent transcriptional repression (data not
shown). This raises the intriguing possibility that KRAB-ZF
proteins are not simply transcriptional repressors, as is
widely thought, given that ZNF224 appears to have both
repression and activation functions with the latter modulated
via interaction with WT1.
Figure 3. ZNF224 and ZNF255 co-localize with different WT1 isoforms. COS7 cells were transfected with p3XFLAG-ZNF224 plus pcDNA3-WT1(2KTS) (A)
or pcDNA3-WT1(+KTS) (B) and with p3XFLAG-ZNF255 plus pcDNA3-WT1(2KTS) (C) or pcDNA3-WT1(+KTS) (D). Twenty-four hours after transfec-
tion, the cells were fixed, permeabilized and the immunofluorescence was performed with anti-FLAG and anti-WT1 (C-19) as primary antibodies. Panel A shows
the overlap of ZNF224-FLAG (red) and WT1(2KTS) signals (green) whereas ZNF224-FLAG does not overlap with the signal of WT1(+KTS) (B).
ZNF255-FLAG has a nuclear localization (red) that partially overlaps with WT1(2KTS) signal (green) (C) but shows a nuclear speckled pattern that precisely
overlaps with the signal of WT1(+KTS) isoform (D).
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Figure 4. ZNF224 specifically enhances WT1-mediated transcriptional regulation and is recruited by WT1 to VDR promoter. A-B: The -960phVDR-LUC was
used as reporter plasmid in transfection assays performed in HeLa cells [(A) lanes 3–13 and (B) lanes 3–10]. The reporter gene is activated by the pcDNA3
WT1(2KTS) (A and B, lane 4). The co-transfection of p3XFLAG-ZNF224 plasmid activates the reporter gene in a dose-dependent manner (A, lanes 5–7),
whereas the p3XFLAG-ZNF255 co-transfection has no effect (B, lanes 5–7). Moreover, the reporter gene is not activated by transfection of p3XFLAG-ZNF224
plasmid alone (A, lanes 8–10). pRL-CMV plasmid was used to normalize the results, pGL4-null empty vector activity indicate the background (A and B, lane 1)
and the pCMV-LUC was the positive control (A and B, lane 2). The p3XFLAG-Nrf2 plasmid was used as a negative control. [(A) lanes 11–13 and (B) lanes 8–
10]. (C) ChIP assay was performed with anti-WT1 antibody (left panel) or anti-FLAG antibody (middle and right panels). Analysis of WT1 and ZNF224 binding
to VDR and AldA-NRE regions was conducted by quantitative real-time PCR. Error bars indicate the mean value+SD of two independent experiments.
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ZNF255 is associated with actively translating
polyribosomes
Evidence is emerging that WT1 is a shuttling protein with
roles in RNA metabolism and possibly in translation (37,38).
The interaction and co-localization of ZNF255 with the
WT1(+KTS) isoform prompted us to evaluate the possibility
that ZNF255 co-localizes with WT1 in the translating ribo-
somes. To this aim, we performed a sucrose gradient analysis,
allowing the separation of various components of the RNA
processing machinery. HEK293 cells were transfected with
plasmids coding for ZNF255-FLAG and WT1(+KTS) pro-
teins and the cellular extract was loaded on a 10–50%
sucrose gradient. Following ultracentrifugation, the collected
fractions were analysed by western blot with specific anti-
bodies. The antibody against L7A, an integral major ribosome
subunit protein, was used as a marker for the ribosome profile
on the gradient. The anti-Hsp90b antibody, a protein that does
not associate with the ribosomes, was used as a negative
control. As shown in Figure 6A, the distribution pattern of
ZNF255 overlapped with WT1 and L7A localization in poly-
somal fractions. On the contrary, endogenous ZNF224 protein
was not associated with the ribosomes, being present in the
same fractions as Hsp90b.
The sucrose gradient was also performed on extracts
treated with ethylenediamine tetra-acetic acid (EDTA),
leading to the dissociation of polysomes and 80S ribosomes
and delocalizing the proteins associated with the translational
complex. Staining with the anti-L7a antibody and monitoring
the absorbance at 260 nm of the gradient fractions
(Figure 6B, upper panel) show that EDTA treatment was
effective in inducing polyribosome dissociation. As shown
in Figure 6B, the ZNF255-FLAG and WT1 sedimentation
profiles were disrupted in EDTA-treated extracts. Under
these conditions, the two proteins were redistributed to
lighter fractions of the gradient, sedimenting primarily with
the 60S and 40S subunits. By comparison, Hsp90b and
ZNF224 localization were not affected by EDTA treatment.
Taken together, these data indicate that cytoplasmic
ZNF255 is associated with the translation machinery, in a
manner similar to WT1, suggesting an involvement in
protein synthesis or in translational regulation.
ZNF255 co-purifies with poly(A) RNP
Given that cytoplasmic WT1 is associated with actively trans-
lating ribosomes and with poly(A) RNP complexes (37,38),
we decided to test whether cytoplasmic ZNF255 could also
be detected in RNP complexes and was capable of binding
to poly(A) RNPs. For this purpose, HEK293 cells were trans-
fected with ZNF255-FLAG and WT1(+KTS) coding plas-
mids, and 48 h after transfection, cellular extracts were
incubated with oligo(dT) cellulose beads, to precipitate
mRNA and its binding proteins. After extensive washing,
the RNA was eluted from the beads with hot diethyl pyrocar-
bonate (DEPC)-treated water. As shown in Figure 7, both
ZNF255-FLAG and WT1 proteins were detected in the
eluate by the western blot analysis (lane 2, middle panels),
confirming an association of these two proteins with the
mRNPs. As expected, the Hsp90 protein is not eluted with
the oligo(dT)-binding complexes (lane 2, lower panel). Inter-
estingly, the ZNF224 protein again shows a different behav-
iour from its isoform, remaining totally unbound by the
beads, as is Hsp90 (lane 2, upper panel). In the control exper-
iments, to exclude the possibility of a non-specific binding of
ZNF255-FLAG and WT1 protein to the oligo(dT) cellulose,
the beads were saturated with oligonucleotides containing
stretches of 10–18 adenines prior to incubation with the
extract (Fig. 7, lanes 3 and 4). Under these conditions, WT1
and ZNF255-FLAG are not detected in these eluates (lane 4,
middle panels). These results indicate that the binding of
WT1 and ZNF255 to the beads is mediated by poly(A) RNA
and once again that ZNF224 has a different behaviour with
respect to the isoform.
Figure 5. ZNF224 knockdown affects the mRNA expression of VDR, an endogenous Wt1 target gene in K562 cells. (A) K562 cells were transfected with
ZNF224 shRNA or scrambled RNA. Forty-eight hours after transfection, RNA and total protein extracts were prepared. ZNF224, aldolase A and VDR
mRNA levels were measured by real-time PCR. Error bars indicate the mean value+SD of two independent experiments. (B) Protein extracts were analysed
by western blot with anti-VDR and anti-GAPDH antibodies.
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Altogether our data point towards a striking specificity
of differential interaction: ZNF255 may participate with
WT1(+KTS) in RNA maturation and post-transcriptional
control, whereas the ZNF224 interaction with WT1(2KTS) is
involved in WT1-mediated transcriptional regulation.
DISCUSSION
Alternative splicing/initiation of the ZNF224 gene can give
rise to at least two different proteins: ZNF224, which is
shown to function as a transcriptional repressor of the aldolase
A gene (2,3,40), and ZNF255, which shows a different subcel-
lular localization and reduced affinity for the aldolase A pro-
moter (4). ZNF255 has been shown to interact with the ZFs
of WT1 to modulate WT1 transcriptional activity (5). Since
ZNF224 shares its ZF domains with the ZNF255 isoform,
we sought to investigate whether ZNF224 also interacted
with WT1.
Our data, derived from endogenous immunoprecipitation,
isoform-specific transfection, confocal immunofluorescence
localization and siRNA knockdown of endogenous expression,
reveal a striking isoform- and subcellular compartment-
specific interaction between the major WT1 isoforms and
ZNF224/255. ZNF224 interacts with WT1 only in the
nucleus and only with the (2KTS) isoform, whereas
ZNF255 can interact with both WT1 isoforms in the nucleus
and cytoplasm, but predominantly with WT1(+KTS), imply-
ing diverging functional roles for the ZNF224/WT1 and
ZNF255/WT1 interactions. Based upon the proposed roles of
the WT1(2KTS) and WT1(+KTS) isoforms, it is tempting
to speculate that the ZNF224/WT1 interaction is involved in
transcriptional regulation, whereas the ZNF255/WT1 inter-
action mediates post-transcriptional regulation, extending
into the cytoplasm. This notion is supported by transfection
assays on a known WT1-regulated promoter, VDR, which
revealed a ZNF224 enhancement of WT1(2KTS)-mediated
transactivation and ChIP experiments, demonstrating that
ZNF224 is recruited into VDR promoter by WT1. Moreover,
siRNA knockdown of ZNF224 resulted in a reduced
expression of endogenous VDR. However, under similar
transfection conditions, ZNF255 had no effect on
WT1(2KTS)-mediated transactivation of VDR, consistent
Figure 6. ZNF255 and WT1 are present in the polysome fractions. The poly-
some gradient was performed in HEK293 cells transfected with the plasmids
coding for ZNF255-FLAG and WT1(+KTS). The protein extracts were
loaded on a 10–50% sucrose gradient. Fifteen fractions were collected from
the top and analysed by western blot using anti-WT1, anti-FLAG and T3 anti-
bodies. As a marker for the ribosome profile, the antibody anti-L7A was used.
The anti-Hsp90b antibody was used as a negative control. The upper panel in
(A) and (B) shows the optical density profiles of the gradient fractions at
260 nm in the absence and in the presence of EDTA, respectively. The analy-
sis shows that a large proportion of ZNF255 and WT1 proteins are found in
polysome fractions, whereas ZNF224 is not (A, upper panels). Polyribosome
dissociation by EDTA modifies L7A, ZNF255-FLAG and WT1 localization
in the gradient fractions, whereas the localization of Hsp90b (B, lower
panel) and ZNF224 (B, upper panel) is not modified. Polysomes, ribosomal
subunits 80s, 60s and 40s and RNP are indicated.
Figure 7. ZNF255 binds the RNA poly A. The HEK293 cells were transfected
with p3XFLAG-ZNF255 and pcDNA3-WT1(+KTS) and the protein extract
was incubated with oligo(dT) cellulose for 2 h. The poly(A)+-binding proteins
were eluted, loaded on an SDS–PAGE and analysed by western blot using
anti-WT1, anti-FLAG and T3 antibodies. ZNF255-FLAG and WT1 proteins
are detected in the poly(A)+-eluted samples (lane 2, middle panels),
whereas ZNF224 and Hsp90b, used as negative control, are not present
(lane 2, upper and lower panels, respectively). As further control, the
oligo(dT) beads were incubated with poly(A) oligonucleotides. Under this
condition, WT1 and ZNF255-FLAG signals were not observed (lane 4,
middle panels). Lanes 1 and 3 represent 1/10 input samples hybridized with
the same antibodies as control.
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with the weaker association observed under confocal
microscopy. Typically, KRAB-ZF proteins are considered as
transcriptional repressors, recently implicated in imprinting
and disease, acting via KRAB-mediated recruitment of
KAP-1 co-repressor complexes containing histone deacety-
lases and methyltransferases (40–42). However, our data indi-
cate that, even in the presence of the KRAB domain, ZNF224
can also function as a transcriptional co-activator, without
directly binding promoter DNA.
With the identification of factors that can modulate the
ability of WT1 to regulate transcription, the complexity of
the role of WT1 in transcriptional regulation is beginning to
be revealed. These factors include DNA-binding proteins,
such as members of the p53 family, and proteins that do not
directly contact DNA, such as BASP1 and Par-4 (19,25,26).
BASP1 was identified as a WT1 transcriptional co-suppressor
(25), whereas Par-4 can act as either a transcriptional
co-activator or as a co-repressor for WT1, depending on the
splice isoform of WT1 (26).
In our co-transfection experiments, ZNF255 displayed a
poor activity in WT1-mediated transcriptional regulation, sup-
porting the hypothesis that ZNF255 interaction with WT1
could be involved in a different molecular process.
However, although our findings differ from the previously
reported inhibition of WT1-mediated transactivation of VDR
by ZNF255 (5), there are several differences between the
two experiments, in particular that they make use of different
cell lines. Although there are numerous examples in the litera-
ture of cell line-dependent differences in WT1 activity
(10,12), the differences between these two studies may have
a biological explanation: our data show that ZNF255 can inter-
act with WT1(2KTS) in the nucleus, albeit less strongly than
the ZNF224 interaction; thus, if, as we propose, WT1/ZNF255
complexes function at a post-transcriptional level, the overex-
pression of ZNF255 might sequester WT1(2KTS) from a
transcriptional compartment, thereby inhibiting WT1 transac-
tivation. Furthermore, as ZNF255 does not contain the
KRAB domain, any repressive function is unlikely to occur
via the classical KRAB-mediated KAP1 co-repressor
pathway. Notwithstanding experimental differences, our
direct comparison demonstrates a clear difference between
the abilities of ZNF224 and ZNF255 to modulate the transcrip-
tional activity of WT1.
Whereas the ZNF224/WT1(2KTS)-specific interaction
suggests a role in transcriptional regulation, the lack of tran-
scriptional activity associated with the ZNF255/
WT1(+/2KTS) interaction and the continued interaction in
the cytoplasm raises the intriguing possibility that ZNF255
is involved in conferring post-transcriptional function on
WT1, leading us to investigate a role for ZNF255 in post-
transcriptional control. Previously, it has been demonstrated
that WT1 could be present in actively translating polysomes
and bound to polyadenylated RNA (37,38). Our experiments
demonstrate that ZNF255, but not ZNF224, co-localizes with
WT1 in the translating ribosomes and is associated with
WT1 in poly(A)+ transcript-containing complexes.
To consider WT1(2KTS) as the ‘transcriptional isoform’
and WT1(+KTS) as the ‘post-transcriptional isoform’ is
likely to be an oversimplification as there is clearly redun-
dancy at the molecular and the genetic levels (10,43). It is
likely that the insertion of KTS affects the binding affinity
of the ZF region for nucleic acids and/or proteins rather than
switching between two distinct states. Such a view is consist-
ent with our findings and with several other studies, including:
Larsson et al. (17) first demonstrated the specific localization
of WT1(+KTS) and WT1(2KTS) and also showed that this
was not 100% discrete; Caricasole et al. (29) showed that
both (+KTS) and (2KTS) isoforms could bind RNA;
Niksic et al. (38) provided evidence that both isoforms
could associate with polysomes and shuttle between the
nucleus and cytoplasm. However, the demonstration that
ZNF255 interacts with WT1 in the nucleus but does not
affect transcription, yet interacts with both isoforms in the
cytoplasm provides an example of how the activity of WT1
isoforms may be modulated by a switch in interacting
partner and that ZNF255 may be part of a WT1-containing
shuttling complex. Furthermore, it is intriguing to note that
the expression of ZNF255 may augment the nuclear speckled
localization of WT1 (+KTS) over that seen in the presence of
ZNF224, although this would require further investigation. It
has been postulated that WT1 may be involved in all stages
of gene expression, being physically associated with, first,
the promoter, then the splicing pre-mRNA and ultimately
present during translation. However, our findings imply that,
if this is the case, different isoforms of ZNF224/ZNF255 par-
ticipate at specific steps.
Despite their prevalence in the human genome, little is
known of the role of human KRAB-ZF genes in development
and disease. Many human KRAB-ZF genes, among which
ZNF224, have no murine homologue, precluding the use of
mouse genetics (gene knockout) to elucidate their function.
One well-characterized KRAB-ZF gene, ZNF74, was ident-
ified as a developmental gene hemizygously deleted in the
majority of patients with DiGeorge syndrome (44,45) and,
recently, polymorphisms within the ZNF74 gene have been
strongly correlated with age-at-onset of schizophrenia (46).
It is tempting to speculate that the recently evolved primate-
specific KRAB-ZF factors are involved in higher, neurologi-
cal functions. Intriguingly, specific functions of the
individual WT1(+KTS) and WT1(2KTS) isoforms in neur-
onal development are beginning to emerge: WT1(+KTS) is
specifically required for the development of olfactory neur-
onal progenitor cells, whereas WT1(2KTS) is specifically
required for the development of neuronal cells of the
embryonic retina (47,48). In addition, our finding that
ZNF224 modulates endogenous VDR expression in the
chronic myelogenous leukaemia (CML) cell line, K562,
may point to a role for this interaction in leukaemia: The
majority of CMLs express high levels of WT1 (49), and it
has recently been demonstrated that vitamin D signalling is
important for stimulating the Hox-A10/MafB pathway con-
trolling haematopoietic differentiation (50). Although we
have found no strong correlations within publicly available
databases, more powerful bioinformatic interrogations focus-
ing on ZNF224/255, WT1 and vitamin D signalling may
prove fruitful, as may an extended analysis searching for
other genes in leukaemic cells potentially regulated by the
WT1/ZNF224 interaction.
A major unresolved question surrounding KRAB-ZF pro-
teins is why they contain more ZFs than necessary to provide
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sequence-specific DNA-binding diversity. Most genomic
studies tend only to consider ZF binding to DNA as a driving
force for the evolution of poly-ZF proteins; however, the
example presented herein demonstrates that protein:protein
interaction is likely to be a significant factor. The complex,
isoform-specific interactions of ZNF224/255 with an ancient
ZF transcription factor described herein suggest that they
have evolved in a specific way to interact with specific isoforms
of a protein conserved throughout vertebrate radiation.
MATERIALS AND METHODS
Cell lines and transfection
HeLa, HEK293 human cell lines and the COS7 monkey cell
line were cultured at 378C with 5% CO2 in Dulbecco’s modi-
fied Eagle’s medium (BioWhittaker) supplemented with 10%
fetal calf serum and 1% penicillin and streptomycin (Bio
Whittaker). K562 cells were cultured in RPMI 1640 with
10% fetal calf serum and 1% penicillin and streptomycin (Bio-
Whittaker). HeLa and HEK293 cells were transfected with
FuGENE Reagent (Roche, Basilea, Switzerland), as rec-
ommended by the manufacturer. COS7 cells used in immuno-
fluorescence assay and K562 cells used in RNA interference
experiments were transfected using Lipofectamine 2000
Reagent (Invitrogen, CA, USA).
Immunoprecipitation assay
For the exogenous proteins, HEK293 cells were co-transfected
with 3 mg of pcDNA3-WT1 (+/2KTS) together with 3 mg of
p3XFLAG-ZNF224 or p3XFLAG-ZNF255 in a 100 mm plate.
Total protein extract was obtained as follows: cells were lyzed
in lysis buffer (25 mM N-2-hydroxyethylpiperazine-N′-2-
ethanesulfonic hepes acid (HEPES) pH 7.4, 137 mM NaCl, 1%
Triton X-100, 10% glycerol, 2.5 mM EDTA, 2.5 mM ethylene
glycol tetraacetic acid (EGTA), 1 mM Na3VO4, 1 mg/ml aproti-
nin, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 5 mM NaF and 5 mM
sodium pyrophosphate) for 30 min on ice. The extract was cen-
trifuged in a microfuge at the maximum speed for 10 min and the
supernatant was used in the immunoprecipitation. K562 cell
lysates for immunoprecipitation assays of endogenous proteins
were prepared as above. Nuclear and cytoplasmic extracts from
K562 and HEK293 cells for the fractioned lysates were prepared
by resuspending pelletted cells in the Cytoplasm Lysis Buffer
(10 mM HEPES pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM dithiothreitol (DTT), 1 mM phenyl methane sulfo-
nyl fluoride (PMSF), 10 mg/ml aprotinin, leupeptin and pepsta-
tin) and incubated for 15 min on ice. After the addition of 0.6%
NP-40, the lysate was vigorously vortexed and centrifugated for
30 s at the maximum speed. The supernatant (cytoplasm) was
collected and the nuclear pellet were transferred in a fresh
tube and incubated on ice for 15 min in the Nuclei Lysis
Buffer (20 mM HEPES pH 7.9, 0.4 mM NaCl, 1 mM EDTA,
1 mM EGTA, 1 mM DTT, 1 mM PMSF, 10 mg/ml aprotinin, leu-
peptin and pepstatin). The nuclear extract was then cleared with
5 min of centrifugation at the maximum speed.
An anti-WT1 antibody (F6 Santa Cruz Biotechnology, CA,
USA) or the IgG rabbit (Santa Cruz Biotechnology) were incu-
bated overnight with 600 mg of protein lysate. The immune
complexes were collected with Protein A/G PLUS Agarose
(Santa Cruz Biotechnology), washed four times with the
lysis buffer and loaded on 8% SDS–PAGE.
To evaluate the interaction of ZNF224 and ZNF255 with
different WT1 isoforms, HEK293 cells were transfected with
3 mg of the plasmids p3XFLAG-ZNF224 or p3XFLAG-
ZNF255 and pcDNA3-WT1(-KTS) or pcDNA3-WT1(+KTS).
The cells were lyzed as described previously and incubated
overnight with C19 antibody or rabbit IgG. ProSep-VA High
CAPACITY beads (Millipore Corporation, MA, USA) were
then added to the samples and incubated for 1 h. The immuno-
precipitated samples were washed and loaded on 8%
SDS–PAGE for western blot analysis with the anti-FLAG
antibody.
Antibodies and western blot
Protein samples from the assays were quantified using the
Bio-Rad protein assay reagent, resolved on SDS–PAGE and
then transferred to Hybond membranes (Amersham Bio-
sciences, NJ, USA). Non-specific binding sites were blocked
for 2 h with 5% milk in tris-tween buffered saline (tTBS)
(5 mM Tris pH 7.5, 15 mM NaCl, 0.1% Tween-20), washed
three times with tTBS and incubated with the following anti-
bodies:
anti-ZNF224/ZNF255 1:1000 (Rabbit polyclonal antibody T3)
anti-WT1 (C19 Santa Cruz Biotecnology) 1:1000
anti c-Myc (Amersham Pharmacia) 1:500
anti-FLAG, M2 (Sigma Aldrich, MO, USA) 1:5000
anti-L7a serum 1:2500
anti-VDR antibody (Santa Cruz Biotechnology) 1:100
anti-GAPDH (OriGene Technologies, Rockville, USA) 1:1000
anti-tubulin (Upstate, Lake Placid, NY, USA) 1:1000
The secondary antibodies were protein A, IgG anti-mouse
and IgG anti-rabbit (Amersham) conjugated to horseradish
peroxidase 1:5000 and detected with ECL western blot detec-
tion system (Amersham).
Luciferase assay
To normalize the luciferase assay pRL-CMV (50 ng) coding
for the renilla luciferase was co-transfected in HeLa cells
plated at a density of 3 × 105 per well in 24-well dishes.
The pGL4-null empty vector (200 ng) was used to evaluate
the background lucyferase activity, whereas the pCMV-LUC
(50 ng) was the positive control for the assay. The
2960phVDR-LUC (200 ng) coding for the firefly luciferase
gene controlled by the VDR promoter was used as a reporter
plasmid. The transcriptional activity of the reporter plasmid
is activated by the co-transfection of the pcDNA3
WT1(2KTS) (300 ng). To evaluate the effect of ZNF224
and ZNF255, 200, 400 or 600 ng of the p3XFLAG-ZNF224
and the p3XFLAG-ZNF255 plasmids were transfected. The
p3XFLAG-Nrf2 plasmid coding for the transcriptional factor
Nrf2 was used as a negative control. The Dual-Luciferase
Reporter Assay System (Promega Corporation, WI, USA)
was performed 48 h after the transfection according to manu-
facturer’s instructions.
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ChIP assay and real-time PCR
HEK293 cells were transfected with pcDNA3WT1(-KTS), or
p3XFLAG-ZNF224, or co-transfected with pcDNA3WT1
(-KTS) and p3XFLAG-ZNF224, respectively. Chromatin
was purified and immunoprecipitated with anti-Flag (Sigma),
anti-WT1 (C19 Santa Cruz Biotechnology) and immunoglobu-
lin G (IgG Sigma) antibodies, as described previously (40).
ChIP samples were then analysed by quantitative real-time
PCR using a Master Mix SYBR Green (Bio-Rad, CA, USA)
and specific primers: for VDR TB3 Fw, 5-CACCTGGCTCA
GCGTCC-3 and TB3 Rev, 5-GCCAGGAGCTCCGTTGGC-3.
For AldA-NRE: AldA-NRE Fw, 5-CCCTCTGTTCCACTG
GGCAAGTGAG-3 and AldA-NRE Rev, 5-CCATTCCAGTT
CCCAGGCCTGGGTG-3.
As a negative control, real-time PCR was done using
GAPDH-specific primers (GAPDH For: 5′-GGTCGTATTGG
GCGCCTGGTCACCA-3′ and GAPDH Rev: 5′-CACACCC
ATGACGAACATGGGGGC-3′). The amount of the immuno-
precipitated DNA fragments derived from VDR promoter or
AldA-NRE region were compared with the negative IgG
control. Real-time PCR data analysis followed the method-
ology previously described (51).
siRNA knockdown and real-time PCR
K562 leukaemia cells were transiently transfected using Lipo-
fectamine 2000 Reagent (Invitrogen) in six-well plates with
2 mg of the short interfering RNA plasmid SH2351C3 (Open
Biosystems, Huntsville, AL, USA) to silence ZNF224/255 or
2 mg of a scrambled RNA. Forty-eight hours after transfection,
the total RNA was isolated by TRIzol Reagent (Invitrogen).
One microgram of each RNA was used for cDNA synthesis
with MMLV reverse transcriptase (Invitrogen). RNA levels
were measured by real-time PCR in a Bio-Rad iCycler using
Master Mix (Bio-Rad) and specific primers for b-actin,
ZNF224 and VDR mRNAs, respectively. For b-actin Fw:
5′-CGA CAG GAT GCA GAA GGA GA-3′ and Rev,
5′-CGT CAT ACT CCT GCT TGC TTG CTG-3′; for
ZNF224 Fw: 5′-GGGCTGTCTTGGCACAATTC-3′ and
Rev, 5′-TTGCCTCCTTGAACGTGGTC-3′; for VDR Fw:
5′-TCCAGTTCGTGTGAATGATG-3′ and Rev, 5′-GAAGGG
TCATCTGAATCTTC-3′.
b-Actin was used as a reference gene for relative quantifi-
cations.
Immunofluorescence assay
COS7 cells were plated on cover slips at a concentration
of 2 × 105 per cover slip and co-transfected with 2 mg of
p3XFLAG-ZNF224 or p3XFLAG-ZNF255, with 2 mg of
pcDNA3-WT1(2KTS) or pcDNA3-WT1(+KTS). Twenty-
four hours after transfection, the cells were washed three
times with cold phosphate buffered saline (PBS) and then
fixed with 2% paraformaldehyde (Sigma) for 10 min. The
slides were washed again and incubated for 10 min in 0.2%
of Triton X-100 to permeabilize the cellular membrane. The
cells were incubated for 20 min in Donkey Serum (Sigma)
diluted 1:20 in PBS to block the aspecific interaction sites of
the antibody. The antibodies used were: anti-FLAG (Sigma)
diluted 1:200 and anti-WT1 (C19 Santa Cruz Biotechnology)
diluted 1:100 in PBS with 1% bovine serum albumin (BSA)
and 0.5% Tween-20 and incubated for 1 h. The secondary
antibodies were the rhodopsin-conjugated donkey anti-mouse
and the fluorescein-conjugated donkey anti-rabbit both
diluted 1:500 in PBS with 1% BSA and 0.5% Tween-20 and
incubated for 30 min. For the visualization of nuclei and to
mount the slides on the cover slips, a Mounting Medium
(Vector Laboratories, Vectashield, CA, USA) with 4′,6-diami-
dino-2-phenylindole (DAPI) was used. The samples were ana-
lysed using the Carl Zeiss LSM510 confocal microscope using
oil immersion lenses.
Polysome extraction and sucrose gradient fractionation
HEK293 cells (2 × 106 cells per 10 cm dish) were transfected
with 3 mg of pcDNA3-WT1(+KTS) and 3 mg of p3XFLAG-
ZNF255. Twenty-four hours after transfection, the cells were
treated for 3 min with 100 mg/ml of cycloheximide, then
washed twice with PBS containing cycloheximide (100 mg/
ml) and harvested and pelletted in a microfuge. The cellular
pellet was resuspended in polysome extraction buffer (PEB),
(20 mM Tris pH 7.5, 100 mM KCl, 5 mM MgCl2, 0.3%
NP-40; 1 mg/ml heparin, 1 mM PMSF, 10 mg/ml aprotinin,
leupeptin and pepstatin) and incubated for 20 min on ice.
Lyzed cells were pelleted by centrifugation for 10 min at
12 000 rpm (Eppendorf microfuge) at 48C and the supernatant
was layered onto 5 ml of 10–50% sucrose gradient prepared in
PEB. The samples were centrifuged in a Beckman MSL 50
rotor at 37 000 rpm in a Beckman Coulter Ultracentrifuge
(SW50.1 rotor) for 2 h and 30 min at 48C. The gradients
were fractionated from the top and the absorbance of cytosolic
RNA (A260) was monitored with a recording spectropho-
tometer. Proteins were precipitated by the addition of trichloa-
cetic acid at 20% final concentration, washed with ice-cold
acetone and resuspended in the loading buffer. The resulting
fractions were then loaded on a 12–8% gradient SDS–
PAGE and analysed by western blot. As a positive control
for the Polysome fractions, the anti-L7a antibody that recog-
nizes the major ribosome subunit protein L7a was used. The
EDTA treatment was performed by adding 20 mM EDTA to
the extract and incubating for 20 min on ice prior to the
sample being loaded onto the gradient that had been sup-
plemented with the same EDTA concentration.
Oligo(dT) chromatography
HEK293 cells (2 × 106 cells per 10 cm dish) were transfected
with 3 mg of p3XFLAG-ZNF255 and 3 mg of pcDNA3-
WT1(+KTS). Forty-eight hours after transfection, the cells
were harvested, washed twice with cold PBS and resuspended
in 2 ml of lysis buffer (10 mM Tris–HCl pH 7.5, 5 mM NaCl,
2 mM MgCl2, 8% glycerole, 1 mM DTT, 0.1% NP-40, 0.1 mg/
ml heparin, 1 mM PMSF, 10 mg/ml aprotinin, leupeptin and
pepstatin). The lysate was incubated for 10 min on ice,
passed through a 22G needle 10 times on ice and centrifugated
in a microfuge for 20 min at 12 000g. The supernatant was
collected and the NaCl concentration was adjusted to
250 mM. Fifty milligrams of oligo(dT) cellulose (Amersham)
was pre-hydrated for 30 min in Lysis Buffer before adding
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to the lysate and incubating with rotation for 2 h at 48C. The
sample was then washed four times with Wash Buffer
(10 mM Tris–HCl pH 7.5, 250 mM NaCl, 2 mM MgCl2),
gently vortexed and finally the poly(A)+ binding proteins
were eluted with 1 ml of 608C DEPC H2O and precipitated
with isopropanol. One-tenth of the supernatant representing
the input was precipitated with isopropanol and loaded on
SDS–PAGE together with the eluted poly(A)+ sample. For
the negative control, the pre-swollen oligo(dT) beads were
saturated with poly(A) oligonucleotides [25 mg poly(A)/
10 mg oligo(dT) cellulose] by 2 h of incubation at 48C and
then incubated with the protein extract.
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a b s t r a c t
The Kruppel-like zinc ﬁnger protein ZNF224 was originally identiﬁed as the transcriptional repres-
sor of the human aldolase A gene. ZNF224 transcriptional repression depends on interaction with the
corepressor KAP-1 and the recruitment of enzyme activities modifying chromatin, in accordance with
repression mechanism of KRAB-ZFP family. Recently, the arginine methyltransferase PRMT5 was demon-ccepted 21 December 2010
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strated to play a crucial role in the transcriptional ZNF224 repressor complex. An alternatively spliced
isoform, ZNF255, arises from the ZNF224 gene. ZNF224 and ZNF255 have a distinct pattern of distribu-
tion within the cell and display a speciﬁc pattern of interaction with different molecular partners. These
isoform-speciﬁc interactions seem to control different cellular pathways. These ﬁndings suggest that
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ZNF224 is a multifunction
isoform-speciﬁc interacti
. Introduction
The zinc ﬁnger protein (ZNF) family, including about 800 mem-
ers, is one of the main groups of proteins with DNA-binding
ctivity. Several ZFPs showadditional domains that speciﬁcally reg-
late the chromatin structure through the recruitment of other
egulatory proteins on the gene promoters (Urrutia, 2003). One
hird of ZNFs, the KRAB-ZFPs, contain a potent transcriptional
epression domain deﬁned as the Kruppel-associated box (KRAB).
his domain usually consists of an A box and a B box and is located
n the amino-terminal sequence (Friedman et al., 1996; Huntley
t al., 2006). Three closely related subfamilies of KRAB-ZFPs have
een found so far: one carrying the A box only, another having
oth A and B boxes, and the third carrying the A box and a diver-
ent “b” box (Urrutia, 2003). The KRAB-ZFPs are mostly localized
n the nucleus and work as repressors of transcription mediated
y RNA polymerases I, II and III (Grondin et al., 1996; Lorenz et al.,
001).Although the functionofKRAB-ZFPs is largelyunknown, theyPlease cite this article in press as: Lupo A, et al. ZNF224: Structure and role
doi:10.1016/j.biocel.2010.12.020
ppear to play important roles in controlling cell differentiation,
poptosis, and cancer.
ZNF224, identiﬁed as the transcriptional repressor of the human
ldolase A gene, is a member of the KRAB-ZFPs (Medugno et al.,
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oi:10.1016/j.biocel.2010.12.020otein and that alternative splicing, sub-cellular compartmentalization and
ay modulate its activity.
© 2010 Published by Elsevier Ltd.
2003). This protein is one of the few examples of KRAB-ZFPs whose
gene target has been identiﬁed and, therefore, is a useful molecu-
lar tool for studying the biological functions of this protein family.
To repress gene transcription, ZNF224 recruits, through its KRAB
domain, the KAP-1 corepressor and the enzymes modifying chro-
matin on thepromoter targets (Medugno and Florio, 2005; Sripathy
et al., 2006). Recently, we identiﬁed PRMT5, an arginine methyl-
transferase type II, as part of the transcriptional repression complex
located on thepromoter of the humanaldolaseA gene (Cesaro et al.,
2009). This ﬁnding provided novel insight into the chromatin mod-
iﬁcations required for the regulation of transcription mediated by
KRAB-ZFPs.
We also demonstrated the existence of an alternatively spliced
isoform arising from the ZNF224 gene, namely ZNF255 and already
known as BMZF2 (Bone Marrow Zinc Finger 2), which shows a
different expression pattern in human tissues, a distinctive sub-
cellular localization and a reduced repression activity compared
with ZNF224 (Lee et al., 2002; Medugno et al., 2007). ZNF224 and
its isoform ZNF255 show a speciﬁc pattern of interaction with the
Wilms’ tumor protein (WT1) isoforms, suggesting a role in control-
ling different cellular pathways (Florio et al., 2010).
The study of some of the known features of ZNF224, such as
structure, expression and interactions with other proteins, might
elucidate its function in physiological and pathological processes.
2. Structureof a multifunctional KRAB-ZFP protein. Int J Biochem Cell Biol (2011),
The ZNF224 protein sequence, which consists of a 707 amino 66
acid open reading frame, originates a protein product of 82kDa 67
and contains 19 tandemly repeated C2H2 zinc ﬁnger domains. The 68
domainmotifs are separatedbya seven-aminoacid-long consensus 69
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Fig. 1. Structure of ZNF224 gene and molecular model of its transcriptional repression complex. (A) Schematic representation of ZNF224 genomic organization, related
mRNAs and proteins. The 6 exons are depicted as boxes. The 5′ UTR of ZNF224 mRNA is formed by fusion of exons I, II and III, whereas the complete coding region is generated
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rrows in mRNA structures indicate the translation start sites. Translation of ZNF
rises from translation of ZNF224 mRNA. (B) Formation of the ZNF224 transcription
odifying activities. Gray triangles and black circles represent the histone modiﬁca
equence (TGEKPYX), called H/C link, which, in turn, connects con-
ecutive ﬁnger domains (Urrutia, 2003). Electrophoretic mobility
hift assays (EMSA) suggest that the domain of ZNF224 that binds
o the aldolase A promoter is located within the zinc ﬁnger motifs
–8 (Medugno et al., 2003). At the NH2 terminus ZNF224 contains
canonical KRAB A motif of 45 amino acids and a divergent b box
Medugno and Florio, 2005).
The genomic organization of the ZNF224 gene is shown in
ig. 1A. Comparison between ZNF224 genomic sequences and its
RNA showed that the mRNA is divided into six exons. The 5′
TR is formed by fusion of exons I, II and III, whereas the com-
lete coding region is generated by fusion of exons IV, V and VI.
he KRAB-A and KRAB-b domains are encoded by different exons
IV and V). Inspection of the mRNA sequence of a second tran-
cript, namely ZNF255, revealed that the 5′ UTR corresponded to
ntron 5 of the ZNF224 gene and the complete coding region was
ontained within exon VI. Translation of ZNF255 mRNA gener-
tes a protein of 622 amino acids. Interestingly, ZNF255 lacks the
RAB domain, but contains the 19 zinc ﬁnger domains (Medugno
t al., 2007). The aforementioned data indicate that the two protein
pecies ZNF224 and ZNF255, differing in the presence or absence
f the KRAB domain, arise from a single gene, in accordance with
he results obtained for other KRAB-containing ZFPs (Mark et al.,
999).
. Expression
The KRAB repression module, the main feature of the KRAB-Please cite this article in press as: Lupo A, et al. ZNF224: Structure and role
doi:10.1016/j.biocel.2010.12.020
FPs, is speciﬁc of the genomes of vertebrate tetrapods. The
xpression proﬁle suggests that the KRAB domain is a rather recent
roduct of evolution and that the expansion of KRAB-ZFPs in ver-
ebrate tetrapods is due to new functions related to differentiation
nd speciation. In the human genome the genes encoding KRAB-he ZNF224 gene and the complete coding region is contained within exon VI. The
RNA generates a protein of 622 amino acids, while a protein of 707 amino acids
ression complex through the recruitment of the corepressor KAP1and the histone
ites.
ZFPsareorganized in clusters andoneof themost extensive clusters
is located on human chromosome 19 (Shannon et al., 2003).
The ZNF224 gene is mapped at the human gene locus 19q13.2
and has no orthologs in mice. This is a common feature of many
human KRAB-ZFPs, suggesting that events of duplication and loss
of commonancestral genes occurred independently after the diver-
gence of the lineages in humans and mice and leading to the
hypothesis that sequence and functional variations in these dupli-
cated proteins play a role in establishing species-speciﬁc traits
(Shannon et al., 2003; Hamilton et al., 2006).
By Northern blotting analysis and semi-quantitative PCR assay,
we found that ZNF224 is ubiquitously expressed in several human
adult and fetal tissues, albeit with quantitative differences. On the
contrary, ZNF255 mRNA appears to be expressed at higher levels in
fetal tissues than in the adult counterparts (Medugno et al., 2007).
4. Biological function
4.1. Transcriptional repressor
Biochemical and functional studies identiﬁed ZNF224 as the
transcriptional repressor of the human aldolase A gene (Medugno
et al., 2003; Medugno and Florio, 2005). It speciﬁcally inter-
acts through the zinc ﬁnger motifs to its cognate DNA-binding
sequence, AldA-NRE, and represses transcription of the human
aldolase A gene. By immunoprecipitation and co-transfection
experiments, we demonstrated that ZNF224-mediated repression
requires the KRAB-A domain and depends on speciﬁc interac-of a multifunctional KRAB-ZFP protein. Int J Biochem Cell Biol (2011),
tion with the KAP1 corepressor molecule. Moreover, treatment 126
with the histone deacetylase inhibitor trichostatin A demonstrated 127
that ZNF224-mediated repression depends on histone deacetylase 128
activity (MedugnoandFlorio, 2005) (Fig. 1B).Werecently identiﬁed 129
the arginine methyltransferase PRMT5 as an additional component 130
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195ig. 2. Known biological functions of the multifunctional ZNF224 protein. While Z
ay play distinct roles in RNA processing in the nucleus and cytoplasm.
f the ZNF224 repressor complex (Cesaro et al., 2009). PRMT5 is
nvolved in the regulation of the gene expression by methylation of
istonesH3andH4, transcription factors andco-regulators (Pollack
t al., 1999; Richard et al., 2005). In addition, PRMT5negatively reg-
lates the expression of genes involved in the cell cycle (Fabbrizio
t al., 2002). In the ZNF224 repressor complex,we demonstrated by
hIP assays that PRMT5 methylates arginine 3 of histone H4 on the
ucleosomes surrounding the promoter region (Fig. 1B). This chro-
atin modiﬁcation is associated with the repression of aldolase
gene expression. Moreover, the association of ZNF224/PRMT5
epression complex with the aldolase A promoter and the methy-
ation status of H4R3 both vary during the cell cycle, conﬁrming
hat ZNF224 plays a signiﬁcant role in the cell-cycle modulation of
ldolase A gene expression and suggesting that PRMT5-mediated
ethylation of histones is required to elicit repression of genes
hose function correlates to the cell cycle. The ZNF224/PRMT5
nteraction region was mapped between the second and third zinc
nger motifs of ZNF224. These domains are conserved in several
RAB-ZFPs and are evolutionarily related, indicating that PRMT5
ay be a key mediator for the regulation of KRAB-ZFP-mediated
epression (Cesaro et al., 2009).
Recently, themitochondrial carrier citrate genewas indicated as
target of ZNF224-mediated transcriptional repression (Iacobazzi
t al., 2009). The ﬁnding that the two so-far-known target genes of
NF224 repressor activity (aldolase A and themitochondrial carrier
itrate) both encode proteins involved in carbohydrate oxidation in
umans leads to suppose a role for ZNF224 in controlling the energy
etabolism.
.2. Interacting proteinsPlease cite this article in press as: Lupo A, et al. ZNF224: Structure and role
doi:10.1016/j.biocel.2010.12.020
While it has been demonstrated that ZNF224 acts as a tran-
criptional repressor, the biological function of ZNF255 isoform is
till largely unknown. Transient transfection and ChIP experiments
emonstrated that ZNF255 shows reduced transcriptional repres-
ion on aldolase A gene compared with ZNF224. Unlike ZNF224,4 function is restricted to regulating transcription in the nucleus, ZNF255 isoform
which shows a homogeneous nuclear distribution, ZNF255 is dis-
tributed throughout the cell and is also present in the nucleoli
(Medugno et al., 2007). The distinctive cellular localization and dif-
ferential repression might indicate a divergent function of ZNF224
and ZNF255 (Fig. 2). This suggestion was strengthened by the iden-
tiﬁcation of speciﬁc interaction between ZNF224 or ZNF255 and
WT1. Two major isoforms of this zinc ﬁnger protein exist, arising
from the insertion or exclusion of the amino acids lysine, threo-
nine and serine (KTS) between the third and fourth zinc ﬁnger. The
WT1(−KTS) isoform is a transcriptional factor that modulates the
expression of a number of genes involved in tissue differentiation,
cell cycle control and apoptosis (Morrison et al., 2005; Loeb et al.,
2002). In contrast, the WT1(+KTS) isoform displays high afﬁnity for
RNA and functions in the RNA metabolism and possibly splicing
(Caricasole et al., 1996; Davies et al., 1998).
By co-immunoprecipitation experiments, we observed the
speciﬁc nuclear interaction between ZNF224 and the WT1 tran-
scriptional isoform (−KTS). The involvement of this interaction in
the transcriptional regulation was demonstrated by cotransfection
and ChIP experiments using a known WT1 target gene, the vita-
min D receptor (VDR). These ﬁndings indicate that ZNF224 acts as
a transcriptional co-activator of WT1 on VDR promoter, providing
theﬁrst example of aKRAB-ZPFprotein that does not act simply as a
transcriptional repressor. In addition, siRNA-mediated knockdown
of ZNF224 in the human erythroleukemia cell line K562 resulted in
a decreased expression of VDR (Florio et al., 2010). Since it is known
that vitamin D can induce apoptosis in leukemia cells (Kizildag
et al., 2009), our ﬁnding suggests a role for ZNF224/WT1 inter-
action in this pathway through the transcriptional activation of
VDR. Conversely, ZNF255 interacts preferentiallywith the +KTS iso-
form, colocalizes with WT1 in translating ribosomes and is presentof a multifunctional KRAB-ZFP protein. Int J Biochem Cell Biol (2011),
in ribonuclear protein complexes (RNP), strongly indicating a role 196
for this interaction in post-transcriptional control (Florio et al., 197
2010). Recently, another molecular partner of ZNF224, the can- 198
cer testis antigen DEPDC1, was identiﬁed (Harada et al., 2010). 199
ZNF224/DEPDC1 complex plays a critical role in bladder carcino- 200
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enesis, repressing the transcription of the A20 gene, a negative
egulator of the NF-kB-mediated antiapoptotic pathway.
. Possible medical applications
ZNF224 has been indicated as a candidate gene in inﬂuencing
ntermediate phenotypes associatedwithAlzheimer’s disease, sug-
esting a further role of the multifunctional protein ZNF224 in the
rogression of degenerative diseases (Shulman et al., 2010). More-
ver, ZNF224, through the interaction with different molecular
artners, takes part in the control of cell cycle-regulated transcrip-
ion (Cesaro et al., 2009), carcinogenesis (Harada et al., 2010) and
poptosis (Florio et al., 2010).
Particularly, our recent ﬁnding that ZNF224/WT1 interaction
odulates VDR expression in K562 cell line may point to a role
or this interaction in leukemia (Florio et al., 2010). WT1 is over-
xpressed in leukemia and plays an oncogenic role through the
ranscriptional upregulation of anti-apoptotic genes such as bag3
Cesaro et al., 2010). The study of ZNF224/WT1 interaction in the
itamin D signalling in leukemic cells, as well as the identiﬁcation
f other genes potentiallymodulated by theWT1/ZNF224 complex,
ould therefore provide novel insight into the understanding of
poptotic process and pave the way to novel molecular treatments
n cancer.
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Role of WT1–ZNF224 interaction in the expression
of apoptosis-regulating genes
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The transcription factor Wilms’ tumor gene 1, WT1, is implicated both in normal developmental processes
and in the generation of a variety of solid tumors and hematological malignancies. Physical interactions of
other cellular proteins with WT1 are known to modulate its function. We previously identified the Kru¨ppel-
like zinc-finger protein, ZNF224, as a novel human WT1-associating protein that enhances the transcriptional
activation of the human vitamin D receptor promoter by WT1. Here, we have analyzed the effects of WT1–
ZNF224 interaction on the expression of apoptosis-regulating genes in the chronic myelogenous leukemia
(CML) K562 cell line. The results demonstrated that ZNF224 acts in fine tuning of WT1-dependent control
of gene expression, acting as a co-activator of WT1 in the regulation of proapoptotic genes and suppressing
WT1 mediated transactivation of antiapoptotitc genes. Moreover, the DNA damaging drug cytosine arabino-
side (ara-C) induces expression of ZNF224 in K562 cells and this induction enhances cell apoptotic response
to ara-C. These findings suggest that ZNF224 can be a mediator of DNA damage-induced apoptosis in
leukemia cells.
INTRODUCTION
Wilms’ tumor gene 1, WT1, which is essential for the embry-
onic development of several organs and structures, encodes
multiple isoforms of DNA-binding protein with zinc-finger
domain (1,2). Two major isoforms of WT1 protein are
designed WT1(+KTS) and WT1(–KTS), because of the in-
sertion or exclusion of three amino acids (KTS) between the
third and fourth zinc fingers; WT1(–KTS) appears to act
mainly as a transcriptional factor, whereas WT1(+KTS) is
involved in RNA processing (3,4).
WT1 is expressed in many tissues, including a small subset
of hematopoietic stem cells (5). Overexpression of WT1 has
been observed in a wide range of solid tumors and hematopoi-
etic malignancies, including acute myeloid leukemia (AML)
and chronic myeloid leukemia (CML) in blastic phase
(6–8), as well as in myelodysplastic syndrome (MDS) (9,10).
The expression of the transcription factor WT1 in leukemic
cells was proposed to exert anti-apoptotic effects (11,12).
Several genes playing a central role in the control of apoptosis
have been proposed as targets of WT1, including the
proapoptotic bcl-2 family members, Bax and Bak (13,14),
bcl-2 itself (15), and the anti-apoptotic genes A1/Bfl-1 (16)
and bag3 (17).
However, despite the identification of these target genes,
little is still known about the molecular mechanism through
which WT1 exerts its regulatory effect on leukemia cell
apoptosis.
The regulatory properties of WT1 are complex since this
transcription factor elicits both activator and repressor func-
tions, depending on the cellular context and interactions with
co-factors. An increasing number of interacting partners has
been proposed to regulate its function, acting as either
co-activators or co-repressors (18). We recently identified
the Kru¨ppel-like zinc-finger protein, ZNF224, as a novel
WT1-associating protein that enhances the transcriptional ac-
tivation of the vitamin D receptor (VDR) promoter by WT1
in the chronic myelogenous leukemia (CML) K562 cell line
(19). This finding prompted us to search for other genes poten-
tially regulated by the WT1/ZNF224 complex in leukemic
cells.
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In this study, we demonstrated that ZNF224 inhibits
WT1-mediated transcriptional activation of the anti-apoptotic
bag3 gene, recently identified as a novel WT1 target gene
(17). Moreover, by short hairpin RNA (sh-RNA)-mediated
knock-down and overexpression of ZNF224 in K562 cells,
we demonstrated that ZNF224 regulates WT1 activity at
several WT1 target genes, acting as a co-activator of WT1
in the regulation of proapoptotic genes and suppressing
WT1-mediated transactivation of anti-apoptotic genes.
Furthermore, we observed that ZNF224 itself could be
modulated by cytosine arabinoside (ara-C), a drug widely
used in the treatment of myeloid leukemia (20) and that
ZNF224 overexpression increases susceptibility to apoptosis
of K562 cells. Our findings demonstrated the role of
ZNF224–WT1 interaction in the modulation of apoptotic
genes expression and suggest that the increased expression
of ZNF224 may represent an important event in the ara-C
mediated-induction of apoptosis. Collectively, data from this
paper disclose a previously unrecognized, novel function of
ZNF224 in the regulation of WT1-mediated transcription of
genes involved in apoptosis, paving the way to potential strat-
egies for treatment of leukemia.
RESULTS
ZNF224 represses WT1-mediated bag3 expression
We recently reported a specific nuclear interaction between
ZNF224 and WT1 and demonstrated that this interaction
enhances WT1-mediated transactivation of VDR promoter,
thus implying that ZNF224 acts as a transcriptional
co-regulator of WT1 (19).
In this work, we investigated whether ZNF224 also affects
WT1-dependent transcriptional regulation of the anti-
apoptotic bag3 gene expression, recently identified as a
novel target of WT1 (17). To this aim we used an HEK293
cell clone, which does not express endogenous WT1, while
stably expressing ZNF224 (CL13 clone) (21) and a C3.3
clone stably expressing a small hairpin RNA (shRNA) specific
for ZNF224. As control, we used a clone generated by stable
transfection of HEK293 cells with the empty vector (CN2
clone) (21). The expression level of ZNF224 in these clones
is shown in Figure 1A. CN2, CL13 and C3.3 clones were
transfected with increasing amounts of the WT1(-KTS) ex-
pression vector and bag3 expression was evaluated at
mRNA and protein levels by quantitative real-time-PCR and
western blot analyzes, respectively. A progressive increase
in bag3 mRNA and protein levels was observed in CN2
clone (Fig. 1B lanes 1, 4, 7 and Fig. 1C left panel), thus con-
firming that WT1 activates bag3 gene expression (17). Con-
versely, in CL13 clone, overexpression of ZNF224
considerably abolished WT1-mediated bag3 induction, as indi-
cated by down-modulation of bag3 transcript and protein ex-
pression (Fig. 1B lanes 2, 5, 8 and Fig. 1C middle panel). In
C3.3 clone, silenced for ZNF224, the increase in bag3
mRNA and protein was higher than in CN2 clone (Fig. 1B
lanes 3, 6, 9 and Fig. 1C right panel), thus indicating an
increased transactivation of WT1 on bag3 gene in the
absence of ZNF224.
To further investigate the effects of ZNF224 on bag3 gene
transcription, we introduced a luciferase reporter plasmid con-
taining bag3 gene promoter into CN2, CL13 and C3.3 clones,
in the presence of increasing amounts of WT1(–KTS) expres-
sion plasmid. Analysis of luciferase activity shows that WT1
was able to activate bag3 promoter in a dose-dependent
manner in CN2 (Fig. 2B lanes 10, 13, 16) as opposed to
CL13 (Fig. 2B lanes 11, 14, 17), in which we observed a dose-
dependent decrease of WT1-mediated transcriptional activity.
As expected, in C3.3 clone an increased luciferase activity
with respect to CN2 clone (Fig. 2B lanes 12, 15, 18 versus
lanes 10, 13, 16) was observed. These findings indicate that
ZNF224 suppresses bag3 gene expression by a transcriptional
mechanism.
ZNF224/WT1 interaction modulates the expression
of apoptosis-regulating genes in K562 cells
To further confirm that WT1/ZNF224 complex modulates
bag3 expression and to better characterize its role in leukemic
cells, we evaluated the effects of the knock-down of ZNF224
on the expression of WT1 target genes. To this aim, K562
cells were transfected with two different shRNA plasmids tar-
geting ZNF224 and a negative control shRNA. The knock-
down of ZNF224 leads to a dramatic increase in bag3 and
A1/Bfl1 anti-apoptotic mRNAs expression, whereas it causes
a decrease in Bak and Bax mRNAs expression, as already pre-
viously observed for VDR, another pro-apoptotic WT1 target
gene (19) (Fig. 3A). The aldolase A mRNA was used as a
control, being known the role of transcriptional repression
exerted by ZNF224 on aldolase A gene transcription (22); as
expected, ZNF224 silencing produced a considerable increase
in aldolase A mRNA expression (Fig. 3A). The changes
observed in mRNAs expression after ZNF224 RNAi were con-
firmed at the protein levels by western blotting (Fig. 3B).
To further verify that ZNF224, besides its role as transcrip-
tional repressor, may act as a cofactor of WT1, we generated a
pool of K562 cells stably transfected with ZNF224 (Fig. 3C)
and evaluated the mRNA levels of WT1 target genes. As
shown in Figure 3E, ZNF224 overexpression is accompanied
by a decrease in bag3 and A1/Bfl1 mRNAs expression and
an increase in Bak, Bax and VDR mRNAs expression. The de-
crease in aldolase A mRNA expression was used as a control
of ZNF224 overexpression (Fig. 3E).
We next confirmed that the ZNF224-mediated modulation
of apoptotic genes was dependent on WT1 expression in
K562 cells. To this aim we transiently transfected a pool of
K562 cells overexpressing ZNF224 with WT1 shRNA
plasmid (Fig. 3D). The depletion of WT1 in this pool of
cells affects the apoptotic gene expression, demonstrating
that ZNF224 requires WT1 to modulate the expression of
bag3, A1/Bfl1, Bax, Bak and VDR (Fig. 3E). On the other
hand, the expression of aldolase A, a direct target of
ZNF224 transcriptional repression, was not influenced by
WT1 knock-down (Fig. 3E).
The above-reported experiments indicate that ZNF224
cooperates with WT1 in the transcriptional modulation
of apoptosis-regulating genes, enhancing gene activation
mediated by WT1 on pro-apoptotic genes and inhibiting
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WT1-mediated transcriptional activation of anti-apoptotic
genes.
WT1 recruits ZNF224 to the promoter of
apoptosis-regulating genes
To determine whether WT1 recruits ZNF224 on endogenous
WT1 target genes we performed chromatin immunoprecipita-
tion (ChIP) experiments. HEK293 cells were transfected
with an expression vector for ZNF224 (p3xFLAG-ZNF224)
(Fig. 4A), or an expression vector for WT1 (pcDNA3WT1
(-KTS) (Fig. 4B), or co-transfected with pcDNA3WT1(-KTS)
and p3xFLAG-ZNF224 (Fig. 4C) and chromatin was immuno-
precipitated with FLAG (Fig. 4A and C) or with WT1 anti-
bodies (Fig. 4B). As expected, we observed by PCR analysis
that ZNF224 was bound to the aldolase A gene promoter
(AldA) and not to the promoter regions of WT1 target genes
(Fig. 4A), thus indicating that ZNF224 alone was unable to
directly bind to these WT1 target promoters; furthermore,
WT1 was bound to Bax, Bak, A1/Bfl1 and bag3 promoter
regions and not to AldA (Fig. 4B). When ZNF224 was over-
expressed along with WT1, it binds WT1 target gene promo-
ters, thus demonstrating that WT1 recruits ZNF224 on these
promoters (Fig. 4C). No bands were observed when a
G3PDH fragment was amplified, using the same chromatin
samples immunoprecipitated with FLAG (Fig. 4A and C)
or with WT1 antibodies (Fig. 4B), thus demonstrating the
specificity of chromatin immunoprecipitation.
This result provides experimental evidence that WT1 and
ZNF224 interact at chromatin level, and this interaction does
not involve direct DNA binding of ZNF224.
Ara-C induces ZNF224 expression in K562 cells
Because the above-reported findings suggest that WT1–
ZNF224 interaction plays a relevant role in apoptotic genes
expression, we decided to investigate whether ZNF224 itself
could be modulated by chemotherapeutic agents. We chose
cytosine arabinoside (ara-C) because it is one of the key
drugs for treatment of leukemia.
K562 cells were exposed to increasing concentrations of
ara-C (0.25, 0.50, 1 mM) for 24, 48 and 72 h after which cell
viability and ZNF224 mRNA levels were measured (Fig. 5).
We observed that exposure to ara-C induced a time-dependent
cell death (Fig. 5A–C).
Then, we evaluated ZNF224 mRNA levels by quantitative
real-time-PCR (Fig. 5D–F). In accordance with our previous
findings that ZNF224 induced pro-apoptotic genes expression,
we observed that levels of this factor also increased in a time
dependent fashion and, apparently, an inverse relationship
subsisted between cell viability and ZNF224 levels. Surpris-
ingly, a dose-dependent effect of ara-C on cell viability was
not observed, even if a dose-dependent increase of ZNF224
was measured. Measurement of cell death by DAPI incorpor-
ation and annexin V binding confirmed the lack of a
Figure 1. ZNF224 overexpression negatively regulates WT1-mediated bag3 expression. (A) Western blot analysis of the ZNF224 protein level in CL13, CN2
and C3.3 HEK293 clones, using anti-ZNF224 antibody (T3). G3PDH is shown as equal loading. Molecular weight to the left. (B) RT-qPCR analysis of the bag3
mRNA expression in CN2, CL13 and C3.3 clones transiently transfected for 48 h with increasing amount of WT1(–KTS) expression vector. mRNA levels of
untransfected clones were referred to as 1 (lanes 1–3). Error bars represent standard deviations of three independent experiments. ∗P, 0.05 versus control. (C)
Western blot analysis of BAG3 and WT1 protein levels in total protein lysates obtained from CN2, CL13 and C3.3 clones transiently transfected with increasing
amount of WT1(–KTS) expression vector for 48 h. G3PDH was used to monitor equal loading conditions. One representative result out of three performed is
presented. Molecular weight to the left.
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dose-dependent effect of ara-C on K562 death (Supplementary
Material, Fig. S1).
To confirm that leukemic cells died by apoptosis, K562
cells were cultured with or without 1 mM ara-C for 72 h after
which we evaluated sub-G1 DNA content and annexin V
binding by FACS analysis and the caspase 3 activition by
western blot. We found that time-dependent increase in
ZNF224 mRNA expression was accompanied by time-
dependent induction of apoptosis and caspase-3 activation
(Fig. 6A–C), thus suggesting that caspase-3 activation was a
direct consequence of ZNF224 induction.
Next, we confirmed that the increase of ZNF224 in
ara-C-treated K562 cells is accompanied by an increase of
proapoptotic VDR, Bax and Bak, and the decrease of anti-
apoptotic bag3 and A1/Bfl-1, as measured by quantitative
real-time-PCR and western blot analysis (Fig. 7A and B).
In addition, ara-C was ineffective in inducing pro-apoptotic
gene expression in pools of K562 cells silenced for ZNF224
(Fig. 7C), notwithstanding the decrease in WT1 mRNA ex-
pression (Fig. 7A and B), thus confirming the role of
ZNF224 as an important mediator of the ara-C-induced activa-
tion of pro-apoptotic genes.
ZNF224 overexpression enhances the apoptotic effect
mediated by ara-C in K562 cells
Next, we evaluated the apoptotic response to ara-C in pools of
K562 cells stably overexpressing ZNF224 (ZNF224-FLAG) or
ZNF224-silenced (ZNF224 silencing) or overexpressing
WT1(–KTS).
These pools of clones and their corresponding controls were
cultured with or without 1 mM ara-C for 72 h and then viability
and apoptosis were analyzed.
As shown in Figure 8A and D, K562 cells expressing
ZNF224–FLAG were significantly more sensitive to the
effects of ara-C on cell viability and apoptosis with respect
to K562 cells not expressing ZNF224–FLAG. According to
these findings, silencing of ZNF224 increased cell viability
and reduced the number of annexin V-positive cells after ex-
posure to ara-C (Fig. 8B and E). These results support a role
for ZNF224 in the apoptotic response to ara-C.
Moreover, we observed that WT1(–KTS) overexpressing
K562 cells are protected, at least partly, from cell death
further confirming the anti-apoptotic role of WT1 (Fig. 8C
and F).
DISCUSSION
Regulation of apoptosis is a critical function of WT1 and is
due at least in part to the modulation of expression of bcl-2
family members (23). WT1 is highly expressed in leukemia
cells and its overexpression is associated with a poor response
to therapy (24,25). We recently showed that WT1 positively
regulates the expression of the anti-apoptotic gene bag3,
by a transcriptional mechanism. WT1-mediated increase in
Figure 2. ZNF224 suppresses WT1-mediated transcriptional activation of bag3 promoter. (A) Schematic representation of the reporter plasmid containing the
bag3 promoter region (21278 to +1) and of the WT1(-KTS) expression vector containing the illustrated region (+400 to +1680) used in transient transfection
experiments. (B) CN2, CL13 and C3.3 HEK293 clones were co-transfected with prom-bag3 reporter and increasing amount of WT1(-KTS) expression vector
(lanes 10–18) or trasfected with prom-bag3 alone as control (lanes 7–9). After 48 h cells were collected and relative luciferase activities were calculated, with
the activity of control cells set as 1 (lanes 7–9) (triplicate determinations). The effect of WT1 on bag3 promoter in CN2, CL13 and C3.3 clones is shown.
pGL4-null empty vector activity indicates the background (lanes 4–6) and pCMV-LUC was the positive control (lanes 1–3). Error bars represent standard devia-
tions of three independent experiments. (C) WT1(–KTS) protein overexpression was evaluated by western blot analysis. G3PDH was used as loading control.
Molecular weight to the left.
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BAG3 protein levels contributes to the pro-survival role of
WT1 in leukemic cells (17).
The effects of WT1 on target gene expression appear to be
isoform-specific, strongly influenced by different cellular con-
texts and by physical interactions with other proteins that are
known to modulate WT1 transcriptional function (18,26–28).
We previously identified the Kru¨ppel-like zinc-finger protein,
ZNF224, as a novel WT1-interacting factor involved in WT1
transcriptional regulation of VDR promoter (19). In this study,
we provide further evidence of ZNF224 acting as a transcrip-
tional co-regulator of WT1 and playing a relevant role in the
control of WT1-mediated expression of apoptosis-regulating
gene in the CML cell line K562, thus pointing to a role for
the ZNF224/WT1 interaction in leukemia. Indeed, chromatin
immunoprecipitation assays revealed that ZNF224 binds to
the promoter of WT1 target genes only if recruited by WT1
itself, thus indicating that ZNF224 acts as a transcriptional co-
factor of WT1, without directly binding to promoter DNA
sequences. A combination of over-expression and knock-down
analyses of both ZNF224 and WT1 in K562 cell line revealed
that ZNF224 exerts a dual effect on the expression of WT1
target genes, acting as a co-activator of WT1 in the regulation
of pro-apoptotic genes and suppressing WT1-mediated trans-
activation of anti-apoptotic genes.
These data demonstrate that ZNF224, beyond its known role
of DNA-binding transcriptional repressor (22), may act in a
DNA binding-independent mode of transcriptional regulation,
through its ability to interact with another transcription factor,
i.e. WT1. Our finding thus reveals a still undiscovered func-
tion for ZNF224 as transcriptional co-regulator.
However, we cannot rule out that ZNF224 could participate
in the regulation of apoptosis also through the direct binding to
promoters of not yet identified target genes, where it acts as a
repressor.
Other Kru¨ppel-like zinc-finger proteins are involved in cell
proliferation, apoptosis and neoplastic transformation (29).
For instance, ZBP-89 has been show to be an important regu-
lator in apoptosis and cell growth and can induce apoptosis
through mechanisms both dependent and independent of p53
(30); ZNF23 inhibits cell cycle progression via up-regulation
of p27kip-1 (31); APAK (ATM ad p53 associated KZNF
protein) specifically inhibits p53-mediated apoptosis (32);
ZNF382 exerts a pro-apoptotic role by repressing NF-KB
and AP1 signaling and by inhibiting the expression of multiple
oncogenes, including the NF-kB upstream factors STAT3,
STAT5B, ID1 and IKBKE (33).
Although KRAB-containing zinc-finger proteins are thought
to function mainly as transcriptional repressors, it has been
Figure 3. ZNF224 and WT1 cooperate in the modulation of apoptotis-regulating genes. (A) RT-qPCR analysis of mRNA levels in K562 cells transfected for 48 h
with two different ZNF224 shRNAs (shRNA C3 and shRNA E7.3) or non-silencing scrambled shRNA, as negative control. Error bars represent standard devia-
tions of three independent experiments. ∗P ¼ 0.05 versus scrambled shRNA; ∗∗P , 0.002 versus scrambled shRNA; ns, not significant (B) Total protein extracts
were analyzed by western blot with the indicated antibodies. G3PDH was used to monitor equal loading conditions. One representative result out of three per-
formed is presented. Molecular weight to the left. (C) Western blot analysis showing the expression of ZNF224–FLAG protein in pool of K562 cells stably
transfected with the expression vector p3XFLAG-ZNF224 (+) or with p3XFLAG empty vector used as control (2). G3PDH was used to monitor equal
loading conditions. Molecular weight to the left. (D) Western blot analysis of WT1 protein level in pool of K562 cells stably transfected with the expression
vector p3XFLAG-ZNF224 and transiently transfected with WT1 shRNA (+) or with non-silencing scrambled shRNA used as control (2). G3PDH was
used to monitor equal loading conditions. Molecular weight to the left. (E) RT-qPCR analysis of mRNA levels in pool of K562 cells overexpressing
ZNF224 (pool ZNF224-FLAG), or in pool of K562 cells overexpressing ZNF224 and transiently transfected with WT1 shRNA (pool ZNF224-FLAG +
WT1 shRNA). The empty vector used as control was: pool of K562 stably transfected with p3XFLAG for the pool ZNF224-FLAG; pool of K562 cells over-
expressing ZNF224 and transiently transfected with scrambled shRNA for the pool ZNF224-FLAG + WT1 shRNA. Error bars represent standard deviations of
three independent experiments. ∗P , 0.05 versus control; ∗∗P ¼ 0.004 versus control; ns: not significant.
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recently reported that ZBRK1 and ZNF263 display activating
as well as repressing effects on target gene transcription, by
yet unknown mechanisms and co-regulators (34,35). Indeed,
several lines of evidence indicate that specific transcription
factors can use distinct combinations of co-regulator com-
plexes and enzymatic activities required for modifying
chromatin machinery, in a cell-, gene-, and promoter-specific
manner.
Deciphering the role of ZNF224 as a transcriptional regula-
tor of WT1, identifying additional components of the WT1/
ZNF224 complex and elucidating how alterations of the
WT1/ZNF224 complex affect the expression of apoptosis-
regulating genes will shed further light into the molecular
mechanisms of apoptosis regulation.
Furthermore, our study revealed that exposure of K562 cells
to ara-C increased ZNF224 transcript in a time- and dose-
dependent manner, suggesting an important role for the
anti-leukemic drug in regulating expression of this protein.
ZNF224 induction is associated with an increase in apoptotic
cell death, which correlates with down-regulation of anti-
apoptotic WT1 target genes such as bag3 and A1/Bfl1 and
upregulation of proapoptotic molecules such as VDR, Bax
and Bak.
On the other hand, the lack of correlation between cell death
values and ara-C doses may be due to a concomitant activation
mechanisms, responsible for apoptosis resistance, that hamper
the expected cell death increase. Such an hypothesis is in
accordance with the notion that K562 are resistant to ara-C
induced cell death (36).
Finally, notwithstanding the heterogeneity of pool of clones,
the increased sensitivity to ara-C induced apoptosis in pools
of clones overexpressing ZNF224 is a further element in
support of the pro-apoptotic role of this zinc-finger protein.
WT1(–KTS) overexpression was able to counteract, at least
in part, the proapoptotic effect of ZNF224 following ara-C
stimulation, thus confirming the relevant role of ZNF224/
WT1 interaction in fine tuning of apoptotic-gene expression.
Taken together, our data support a relevant role for ZNF224
in ara-C induced apoptosis of leukemia cells and suggest that
ZNF224 could provide a critical link between ara-C induced
DNA-damage and the expression of pro-apoptotic genes in
leukemia cells.
A better definition of the molecular mechanism coupling
ara-C-induced DNA damage to the initiation of cell death
could lead to the development of new therapeutic drugs used
for the treatment of leukemia.
MATERIALS AND METHODS
Cell culture and stable transfection
HEK293 human cell lines were cultured in Dulbecco’s modified
Eagle’s medium (Bio-Whittaker, Verviers, Belgium) supplemen-
ted with 10% fetal calf serum, 100 mg/ml streptomycin-penicillin
Figure 4. ZNF224 is recruited by WT1 to apoptotic target gene promoters. Chromatin immunoprecipitation assay was performed with anti-FLAG antibody (A
and C) or anti-WT1 antibody (B). Immunoprecipitation with non-specific IgG were used as negative control. Non-immunoprecipitated chromatin was used as
total input control. PCR analysis was used to evaluate the WT1 and ZNF224 binding to AldA, A1/Bfl-1, bag3, Bax and Bak promoter regions, using specific
primers. As control of specificity of immunoprecipitated chromatin, PCR was performed using G3PDH primers. Results are representative of two independent
experiments. Size, in bp, of the PCR products to the left. (D) Total protein extracts from HEK293 transfected with p3XFLAG-ZNF224 and from HEK293
co-transfected with p3XFLAG-ZNF224/pcDNA3WT1(-KTS) were analyzed by western blot with the indicated antibodies. G3PDH was used to monitor
equal loading conditions. Molecular weight to the left.
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mix (Bio-Whittaker) at 378C in 5% CO2. The stable clone from
HEK293 expressing p3XFLAG-ZNF224 (CL13) and clone from
HEK293 cells transfected with empty p3XFLAG (CN2) were
obtained as described (21).
The chronic myeloid leukemia cell lines K562 were cultured
in RPMI 1640 supplemented with 10% fetal calf serum and
100 mg/ml penicillin-streptomycin mix (Bio-Whittaker) at 378C
in 5% CO2. To obtain pools of clones permanently expressing
3XFLAG-ZNF224, K562 cells were transfected with
p3XFLAG-ZNF224 G418-selectable plasmid using HiPerFect
Reagent (Qiagen, Hilden, Germany). Transfected cells were
selected in medium containing 800 mg/ml G418 (Promega,
Madison, WI, USA) for 4 weeks. Dead cells were removed by
Ficoll density gradient centrifugation (GE Healthcare Bio
Science AB, Sweden, Uppsala). The positive pool of clones
was analyzed by western blotting using M2 anti-FLAG antibody
(Sigma-Aldrich, MO, USA). As negative control, we selected
pools of K562 cells stably transfected with the empty
p3XFLAG G418-selectable plasmid.
We used pool of K562 cells transduced with a retroviral
vector encoding for WT1(–KTS) or with the control empty
vector (pMIG), as described (37).
ShRNA-mediated knock-down
To obtain stable ZNF224 gene silencing (clone C3.3), we
transfected 2 × 106 HEK293 cells with 10 mg of short interfer-
ing RNA plasmid SH2351C3 (ZNF224 shRNA) (Open Bio-
systems, Huntsville, AL, USA), using Lipofectamine
Reagent (Invitrogen, Carlsbad, CA, USA), according to the
manifacturer’s protocol. The cells were grown in selective
medium until colony formation. Positive clones were analyzed
by western blotting using anti-ZNF224 antibody (T3). Pools of
K562 clones silenced for ZNF224 (ZNF224 shRNA) were
obtained by transfection of 1.5 mg of short-interfering RNA
plasmid SH2351C3 (Open Biosystem) using the HiPerFect
Reagent (Qiagen), according to the manufacturer’s protocol;
transfection of a non-silencing shRNA (scrambled shRNA)
was used as negative control (Open Biosystem). Transfected
cells were selected in medium containing 500 mg/ml Puro-
mycin (Promega) for 4 weeks. Dead cells were removed by
Ficoll density gradient centrifugation (GE Healthcare). Posi-
tive clones were analyzed by western blotting using
anti-ZNF224 antibody (T3).
K562 cells were transiently transfected using the HiPerFect
Reagent (Qiagen) in 12-well plates with 1.5 mg of the short-
interfering RNA plasmid SH2351C3 to silence ZNF224, or
1.5 mg of the short-interfering RNA plasmid SH25dE-10 to
silence WT1, or 1.5 mg of non-silencing negative control
(scrambled shRNA) as control. All plasmids were purchased
from Open Biosystems. Cells were collected 48 h after trans-
fection.
RNA isolation, reverse transcription and real-time PCR
Total RNA was isolated using TRIzol Reagent (Invitrogen,
Carlsbad, CA, USA), according to the manufacturer’s proto-
col. One microgram of each RNA was reverse transcripted
using QuantiTect Reverse Transcription Kit (Qiagen), accord-
ing to the manufacturer’s protocol. Real-time PCR was carried
out in a iCycler Thermal Cycler (BioRad, Berkeley, CA, USA)
using the SYBR Green I Master Mix (BioRad) and specific
primers for: ZNF224 (Fw 5′-gggctgtcttggcacaattc-3′, Rev
5′-ttgcctccttgaacgtggtc-3′); WT1 (Fw 5′-gtgaaaccattccagtgtaa
aac-3′, Rev 5′-gccaccgacagctgaagggc-3′); bag3 (Fw 5′-cctgttag
ctgtggttg-3′, Rev 5′-aacatacagatattcctatggc-3′); VDR (Fw
Figure 5. Dose and time-course of ara-C induced ZNF224 expression. K562 cells were treated with 0.25 mM, 0.50 mM, 1 mM ara-C for 24, 48 and 72 h. NT:
untreated K562 cells collected at the indicated times. (A–C) Viability as determined by trypan blue exclusion. The results are means + - SD from two impendent
experiments. (D–F) RT-qPCR analysis of ZNF224 mRNA expression in K562 cells treated with 0.25 mM, 0.50 mM, 1 mM ara-C for the indicated times. Error
bars represent standard deviations of two independent experiments.
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5′-tccagttcgtgtgaatgatg-3′, Rev 5′-gaagattcagatgacccttc-3′);
A1/Bfl-1 (Fw 5′-cggcatcattaactggggaag-3′, Rev 5′-ctagaagt
tacaggaaagatc-3′); Bak (Fw 5′-tgaaaaatggcttcggggcaa-3′, Rev
5′-ctctcaaacggctggtggcaatc-3′); Bax (Fw 5′-tcaggatgcgtc
caccaagaaag-3′, Rev 5′-gcaaagtagaaaagggcgacaacc-3′);
matrin3 (Fw 5′-cattctaataaggagtggagtc-3′, Rev 5′-tgctagtttccac
tctgcctt-3′); aldolase A (Fw 5′-tcaaccacactccgtccacg-3′, Rev
5′-gtagcaagttccggtgcttc-3′); b-actin (Fw 5′-cgacaggatgcaga
aggaga-3′, Rev 5′-cgtcatactcctgcttgcttgctg-3′). b-actin house-
keeping gene was used as a reference gene for relative quan-
tification. All real-time PCR reactions were performed in
duplicate.
To analyze the expression of ZNF224 mRNA levels in
K562 cells treated with ara-C and in the untreated controls,
total RNA was isolated using the RNeasy Mini Kit (Qiagen)
according to the manufacturer’s protocol. 0.5 mg of total
RNA was reverse transcribed using High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems Inc., Foster
City, CA, USA) with random hexamer primers according to
the manufacturer’s instructions. Quantitative PCR was
carried out using TaqMan probe-based chemistry (Applied
Biosystems); the probe for ZNF224 (Hs00273760) and the en-
dogenous control b-actin (Hs99999903_m1) were purchased
as Assay-on-Demand (Applied Biosystems). The amplification
reactions were all performed in triplicates in an ABI Prism
7000 Sequence Detection System (Applied Biosystems).
Data were collected and analyzed using the Sequence Detector
v.1.1 software (Applied Biosystems).
The relative quantification in gene expression was deter-
mined using the DDCT method (38). Normalization: DCT ¼
CT(sample)-CT(endogenous control); DDCT ¼ DCT
(sample1)-DCT(sample2). Relative quantification ¼ 22DDCT.
The efficacy of the PCR amplification of controls and test
was identical; parallelism of standard curves of the control
and test was confirmed.
Statistical analysis
P-value was determined by Student’s t test. All P-values were
considered significant when P, 0.05.
Transient transfection and luciferase-reporter assays
The HEK293 stable clones CL13, CN2 and C3.3 were transient-
ly transfected using Lipofectamine Reagent (Invitrogen) in
12-well plates with 0.2 mg of a luciferase reporter plasmid con-
taining the proximal bag3 promoter (PromBag3-Luc) and 0.4,
0.8 and 1.2 mg of WT1(–KTS) expression plasmid. The
pGL4-null empty vector (0.2 mg) was used to evaluate the back-
ground luciferase activity, whereas the pCMV-LUC (50 ng) was
the positive control for the assay. To normalize the luciferase
assay a pRL-CMV plasmid (20 ng) coding for the renilla luci-
ferase was used. The Dual-Luciferase Reporter Assay System
(Promega Corporation, WI, USA) was performed 48 h after
the transfection according to manufacturer’s instructions.
Results are representative of two independent experiments.
Western blot analysis
Total protein extract was obtained as follow: cells were
washed twice with cold PBS, then were lysed in lysis buffer
(10 mM HEPES pH7.8, 250 mM NaCl, 5 mM EDTA pH 8.0,
1% Nonidet P-40, 1 mM sodium orthovanadate and 50 mM
sodium fluoride) and protease inhibitors [1 mM phenylmethyl-
sulfonyl fluoride (PMSF), 1 mg/ml aprotinin and 1 mg/ml pep-
statin A] for 30 min on ice. The extract was centrifuged in a
microfuge at maximum speed for 10 min and the supernatant
was quantified using the BioRad protein assay reagent,
resolved on SDS–PAGE and then transferred to Hybond
membranes (Amersham Biosciences, NJ, USA). Non-specific
binding sites were blocked for 2 h with 5% milk in Tris–
Tween buffered saline (tTBS) (5 mM Tris pH 7.5, 15 mM
NaCl, 0.1% Tween-20), washed three times with tTBS and
incubated with the following antibodies:
anti-FLAG (M2) from Sigma-Aldrich, 1:1000
anti-VDR (D-6) from Santa Cruz Biotechnology, 1:500
anti-GAPDH (7-B) from Santa Cruz Biotechnology,
1:1000
anti-BAX (B-9) from Santa Cruz Biotechnology, 1:500
For these primary antibodies the secondary antibody
was goat-anti-mouse IgG (H+L)-HRP conjugated
(BioRad170-6516) antibody, 1:3000, detected with an
ECL western blot detection system (Amersham Bios-
ciences).
Figure 6. Time-course of ara-C induced apoptosis. K562 cells were treated
with 1 mM ara-C and analyzed after 24, 48 and 72 h. (A) Apoptosis as deter-
mined by annexin V-APC staining followed by flow cytometry. Error bars rep-
resent standard deviations of three independent experiments. (B) Cell
apoptosis was measured by staining with propidium iodide and flow cyto-
metric analysis. Error bars represent standard deviations of three independent
experiments. (C) Western blot analysis of cleaved caspase-3. One representa-
tive result out of three performed is presented. Molecular weight to the left.
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anti-WT1 (C19) from Santa Cruz Biotecnology, Santa
Cruz, CA, USA, 1:500
anti-BAG3 (TOS-2) from BioUniverSa s.r.l., Fisciano,
Italy, 1:10000
anti-A1/BFL-1 (PRS3873) from Sigma-Aldrich,
1:1000
anti-Cleaved caspase-3 (Asp175) from Cell Signaling,
Denvers, USA, 1:1000
anti-BAK (B5897) from Sigma-Aldrich, 1:2000
For these primary antibodies, the secondary antibody was
goat-anti-rabbit IgG (H+L)-HRP conjugated (BioRad170-
6515) antibody, 1:3000, detected with an ECL western blot
detection system (Amersham Biosciences).
The western blot for ZNF224 was performed using the
anti-ZNF224 (T3) antibody (Rabbit polyclonal antibody)
(39). Non-specific binding sites were blocked for 2 h in
SuperBlock blocking solution buffer in PBS (Thermo Scientif-
ic) with 0.1% Tween-20. SuperBlock blocking solution buffer
was used in incubation steps with primary and secondary anti-
bodies. The primary antibody was diluted in a ratio 1:500.
The secondary antibody was goat-anti-rabbit IgG
(H+L)-HRP conjugated (BioRad170-6515) antibody
(1:3000), detected with an ECL western blot detection
system (Amersham Biosciences).
Chromatin immunoprecipitation (ChIP) assay
The ChIP assay was performed as previously described (21).
Briefly, cross-linked chromatin was prepared from HEK293
cells transfected with 3XFLAG-CMV-7.1-ZNF224 or
Figure 7. Modulation of apoptosis-regulating genes by ara-C. (A) RT-qPCR analysis of mRNA levels in K562 cells treated with 1 mM ara-C for 72 h. NT:
untreated K562 cells collected at 72 h used as control. mRNA level of matrin3 was measured to demonstrate the specificity of ara-C effect on apoptosis-
regulating genes. Error bars represent standard deviations of three independent experiments. ∗P, 0.05 versus control; ∗∗P ¼ 0.006 versus control; ns, not sig-
nificant. (B) Total protein extracts were analyzed by western blot with the indicated antibodies. G3PDH was used to monitor equal loading conditions. One
representative result out of three performed is presented. Molecular weight to the left. (C) RT-qPCR analysis of mRNA levels of pools of K562 cells silenced
for ZNF224 and treated with 1 mM ara-C for 72 h (ZNF224 shRNA+ara-C 1 mM) or of pools of K562 cells stably transfected with scrambled shRNA treated
with 1 mM ara-C for 72 h (scrambled shRNA+ara-C 1 mM) used as negative control. Error bars represent standard deviations of two independent experiments.
∗P, 0.05 versus scrambled shRNA treated with ara-C.
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pcDNA3WT1(-KTS), or co-transfected with 3XFLAG-
CMV-7.1-ZNF224 and pcDNA3WT1(-KTS). Briefly, 5 ×
107 cells were cross-linked with 1% of fixing solution (11%
HCHO, 100 mM NaCl, 1 mM EDTA, 0.5 mM EGTA, 50 mM
HEPES pH 8.0) and harvested in 1.5 ml of cell lysis buffer
(5 mM PIPES pH 8.0, 85 mM KCl, 0.5% Nonidet P-40) with
protease inhibitors (1 mM phenylmethylsulfonyl fluoride
(PMSF), 1 mg/ml aprotinin and 1 mg/ml pepstatin A). Nuclei
were collected and resuspended in 300 ml of nuclear lysis
buffer (50 mM Tris–HCl pH 8.0, 10 mM EDTA, 0.8% SDS
and protease inhibitors). The DNA was sheared by sonication
to an average length between 200 and 1000 bp. Sonicated
DNA was diluted 3-fold in dilution buffer (10 mM Tris–
HCl, pH 8.0, 0.5 mM EGTA, 1% Triton X-100, 140 mM
NaCl, protease inhibitors) and precleared with protein A/G
plus-agarose (Santa Cruz Biotechnology) at 48C for 1 h.
The precleared extract obtained from cells transfected with
3XFLAG-CMV-7.1-ZNF224 or co-transfected with
3XFLAG-CMV-7.1-ZNF224 and pcDNA3WT1(-KTS) was
divided in two aliquots. One aliquot was incubated with 3 mg
of FLAG M2 mouse antibody (Sigma-Aldrich), and the other
was incubated with 3 mg of anti-mouse IgG (Sigma-Aldrich),
used as control. The precleared extract obtained from cells
transfected with pcDNA3WT1(-KTS) was divided in two ali-
quots and incubated with 5 mg of rabbit anti-WT1 antibody
(C19 Santa Cruz Biotechnology), or with 5 mg of anti-rabbit
IgG (Sigma-Aldrich), used as control.
Beads were collected by centrifugation and then washed
three times with washing buffer P1 (30 mM NaCl, 50 mM
Tris–HCl pH 8.0, 1 mM EDTA, 10%glycerol, 0.1% Nonidet
P-40, protease inhibitors), twice with washing buffer P2
(50 Mm Tris–HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 10%
glycerol, 0.1% Nonidet P-40, protease inhibitors) and twice
with TE buffer (1 mM Na-EDTA, 10 mM Tris–HCl pH8.0).
The first supernatant of the IgG control served as the total
input control for the PCR analysis effectiveness. The beads
were taken up in 100 ml of TE. 1 mg of RNase was added,
and cross-links were reversed at 658C overnight. The next
day, samples were adjusted to 0.5% SDS and 0.5 mg/ml pro-
teinase K and incubated for 3 h at 508C. DNA was purified
by phenol–chloroform extraction. ChIP samples were then
analyzed by PCR using 2 ml of immunoprecipitated material,
the input control diluted in a ratio 1:200, and specific
primers for: Bax (Fw 5′agatgctcattggacagtcacg-3′, Rev
5′-gagtttctgcccctcagtgct-3′); Bak (Fw 5′-gatggagtcttgcactgt
cacc-3′, Rev 5′-ttctggctaacatggtgaaacc-3′); bag3 (Fw 5′-agtcc
agctcgtccggcttc-3′, Rev 5′-ggccagttgctacctccct-3′); A1/Bfl-1
primer sequences are described in (16). Aldolase A primer
sequences are described in (22); as control of immunoprecipi-
tated chromatin specificity, PCR was performed using G3PDH
primers (Fw 5′-ggtcgtattgggcgcctggtcacca-3′, Rev 5′-cacacc
catgacgaacatgggggc-3′). Results are representative of two
independent experiments.
Analysis of viability and apoptosis by flow cytometry
Apoptosis of K562 cells, pools of K562 cells stably overex-
pressing ZNF224 (ZNF224-FLAG) or stably transfected with
Figure 8. ZNF224 enhances ara-C induced apoptosis. (A and D) The cell viability and the apoptosis of K562 cells expressing or not expressing ZNF224-FLAG,
measured after treatment with 1 mM ara-C for 72 h. (B and E) The cell viability and the apoptosis of pools of K562 cells stably transfected with ZNF224 shRNA
or scrambled shRNA, measured after treatment with 1 mM ara-C for 72 h. (C and F) The cell viability and the apoptosis of pools of K562 cells retrovirally
transduced with WT1(–KTS) or control empty vector (pMIG), measured after treatment with 1 mM ara-C for 72 h. NT, untreated cells collected at 72 h. The
cell viability was determined by trypan blue exclusion. The cell viability was calculated as a percentage from the viability of the untreated cells (NT) set as
100%. Apoptosis was determined by annexin V-APC positivity followed by flow cytometry. Error bars represent standard deviations of three independent experi-
ments. ∗P , 0.05, ∗∗P , 0.005 versus untreated (NT) cells.
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ZNF224 shRNA, pool of K562 cells retrovirally transduced
for WT1(–KTS), was induced by cytosine arabinoside
(ara-C) (Sigma-Aldrich). To this aim, cells were plated at a
density of 2.5 × 105/well in 12-well plates. Cell number was
counted in a Bu¨rker chamber and viability was determined
by trypan blue exclusion.
For assessment of apoptosis, 2 × 105 cells were stained with
propidium iodide (Sigma-Aldrich) and analyzed by flow cyto-
metry as described (40).
For annexin V staining, 3 × 105 cells were rinsed twice in
cold PBS with Ca2+ and Mg2+, than was resuspending in
cold annexin V-binding buffer (5 M NaCl, 1 M CaCl2, 1 M
HEPES buffer/NaOH pH 7.4) and stained with Annexin
V-APC (550474, BD Pharmingen), DAPI (4′,6-diamidino-
2-phenylindole) (D9564, Sigma-Aldrich), and 7AAD
(7-amino-actinomycin) (559925, BD Pharmingen). This
allows for the discrimination of live cells (DAPI impermeable)
from apoptotic cells (annexin V and DAPI positive cells) and
necrotic cells (7AAD and DAPI positive cells). Following incu-
bation on shaker in the dark for 15 min at 48C, cells were ana-
lyzed on an FACS Aria flow cytometer (BD Biosciences
Immunocytometry System).
SUPPLEMENTARY MATERIAL
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